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ABSTRACT
Breast cancer is the most frequently diagnosed and second leading cause of cancer
deaths in women, accounting for 25% of cancer diagnoses and 15.4% of cancer deaths in
developed countries. Thus, early detection of breast cancer through screening has become
increasingly important in mortality reduction efforts. Yet, mammography has faced
considerable controversy in balancing the benefits and harms associated with screening.
Digital breast tomosynthesis has emerged as an important imaging technique which,
compared to standard mammography alone, reduces recall rates and false positives, and
improves cancer detection. Additional cancers detected with tomosynthesis have been
poorly characterized in the literature to date. To assess the effectiveness of screening with
adjunct tomosynthesis, we propose to utilize our large database to characterize cancers
detected in true positive recalls. Our findings will help clinicians make well-informed
decisions for further management of women with mammographically suspicious or
inconclusive findings, and contribute to future screening guidelines.

vii

CHAPTER I: INTRODUCTION
1.1 Background
Breast cancer is the most prevalent cancer in women worldwide, with an estimated 5year prevalence of 6.2 million women (36.3%).1 It is also the most frequently diagnosed
cancer in women worldwide: according to the most recent global incidence data from
2012, breast cancer accounts for 25% of all cancer diagnoses, and is the most frequent
cause of cancer mortality in less developed regions.2 In developed nations such as the
United States, breast cancer is second only to lung cancer as the most common cause of
cancer mortality in women, accounting for 198,000 cancer deaths annually.2 Thus,
accurately identifying women at increased risk of developing breast cancer for targeted
screening, in addition to effective population-based screening programs, remains a high
priority in the United States and abroad.
For over a decade, conventional two-dimensional (2D) full-field digital
mammography (FFDM) has been widely accepted as the most effective screening
technique for the detection of breast cancer and mortality reduction in asymptomatic
women.3 Experts agree that standard screening mammography reduces breast cancer
mortality by 12% to 33%.4,5 2D mammography is also the most common technique for
measuring and classifying breast density using the Breast Imaging Reporting and Data
System (BI-RADS) established by the American College of Radiology (ACR).6 The
identification of women with dense breasts has become increasingly important in breast
cancer screening efforts: a recent systematic review from the United States Preventive
Services Task Force (USPSTF) estimates that 27.6 million American women 40 to 74
years of age have dense breasts (43%).7 Independent of other risk factors, women with
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extremely dense breast tissue have a 3- to 5-fold increased risk of developing breast
cancer, as compared to women with fatty breast tissue.8,9
Standard 2D mammography has several limitations, particularly in women with dense
breasts. Superimposition of breast tissue can obscure areas of malignancy, and may cause
otherwise normal tissue to appear mammographically suspicious.10 This masking effect is
most pronounced in women with dense breasts. Higher breast density is associated with
decreased mammographic sensitivity and specificity compared to women with non-dense
breasts.11 Overall, FFDM has low sensitivity, high false positive recall rates, and limited
utility for screening in women with dense breasts.12,13 Up to 30% of breast cancers are not
detected using conventional FFDM, highlighting the need to enhance the performance of
screening mammography.14
Three-dimensional (3D) digital breast tomosynthesis (DBT), also known as 3D digital
mammography, has emerged as a promising and improved technique for breast cancer
screening and detection.15,16 In 2011, the US Food and Drug Administration (FDA)
approved the use of DBT in combination with FFDM for the screening and diagnosis of
breast cancer.17 In 2013, the FDA approved the use of DBT with reconstructed synthetic
2D (s-2D) images, a technique developed to address the burden of doubled radiation dose
exposure in women undergoing dual acquisition DBT and FFDM, the means by which
DBT has been traditionally acquired.7 Several studies have observed non-inferior or
superior performance metrics from DBT with s-2D as compared to the conventional dual
acquisition DBT and FFDM.18-20
DBT, in conjunction with FFDM or as a standalone with reconstructed s-2D images,
is associated with increased cancer detection rates and reduced false positive recall rates
2

from screening – regardless of age or breast density.19-21 DBT has also been shown to
increase the positive predictive value from recall.22-24 Importantly, while DBT increases
cancer detection rates, it does not appear to increase detection of in situ carcinomas,
alleviating concerns regarding further over-diagnosis and overtreatment from
screening.25-27 Despite the growing evidence for the utility of DBT for screening, the
2016 USPSTF guidelines suggest that more evidence is needed before recommending the
use of DBT as a primary screening method in practice.4
1.2 Statement of the Problem
While DBT has been shown to increase overall and invasive cancer detection rates,
few studies have characterized the sizes, histologic types and grades, lymph node status,
and receptor phenotypes of cancers detected with DBT versus FFDM alone.10,15,22,24
A valuable way to assess this important gap in knowledge is to determine the number
of true positive cases from recall detected with DBT versus FFDM alone, and to
characterize the tumors detected in this population. Evaluation of this cohort is an
important way to assess the effectiveness of screening with DBT versus FFDM, since
these cases represent women with indeterminate mammographic findings that require
further imaging and/or biopsy. When such recalls do not lead to a cancer diagnosis, they
are considered false positives, and contribute to the harms of mammography by incurring
patient discomfort, risk, cost, time, and stress.28 Although screening with DBT is known
to increase the detection of cancer while reducing recall rate, current literature regarding
the characterization of cancers detected with DBT versus FFDM alone is lacking.29,30

3

1.3 Goals and Objectives
The proposed study aims to compare the effectiveness of screening with DBT versus
FFDM alone for the detection of breast cancer by characterizing cancers in true positive
cases: biopsy-proven cancers in women recalled from screening, defined as
mammographic ACR BI-RADS category 0 (inconclusive; requires recall for additional
imaging).31 Henceforth, women recalled from screening will be referred to as BI-RADS 0
cases for brevity.
The primary outcomes to be measured in the population of interest, BI-RADS 0
cases, are the positive predictive value from recall (PPV1) and the cancer detection rate
(CDR) per 1000 women screened, as detected with DBT versus FFDM alone. While the
CDR will be measured, we are not powered to detect a statistically significant difference
in cancer detection across modalities given our sample size. Secondary outcomes, which
are of chief interest, include: tumor pathologic size and stage at diagnosis; histological
type and grade of cancers; axillary lymph node status and receptor phenotype of invasive
cancers, to be evaluated in true positive BI-RADS 0 cases. To determine our outcomes of
interest, the total number of women recalled from screening (BI-RADS 0 cases) and the
overall recall rate (RR, %) per modality have already been measured and reported.32
This study’s outcomes will help to better characterize cancers detected from
screening with DBT versus FFDM alone; inform future breast cancer screening efforts
and guidelines; and aid clinicians in making well-informed decisions for the management
of women with suspicious or inconclusive mammographic findings.

4

1.4 Hypotheses
Primary Hypothesis: Cancers detected in women recalled from screening with DBT
versus FFDM alone will yield significantly higher PPV1, as measured by the number of
biopsy-proven true positive BI-RADS 0 cases per total BI-RADS 0 cases.29
Our study is not powered to detect significant changes in cancer detection, as
evidenced by studies of similar size (see Chapter II for further discussion).3 Therefore,
we do not expect to detect a statistically significant increase in CDR from screening with
DBT versus FFDM alone, though a non-significant increase is likely to be observed.3,15,24
Secondary Hypotheses: True positive BI-RADS 0 cases detected from screening with
DBT versus FFDM alone will yield (statistically significant):
a) Smaller mean pathologic sizes of tumors.33
b) Lower grade of in situ cancers31 (nuclear grade) and invasive cancers (Nottingham
histologic grade) at time of diagnosis.33
c) No significant difference in the proportions of histological types of in situ or
invasive cancers (ductal, lobular, other).33-35
d) Smaller proportions of invasive cancers with spread to axillary lymph nodes.33,36
e) Lower pathologic stage at diagnosis.
f) No significant difference in the proportions of receptor phenotypes for invasive
cancers (ER+/PR+ or luminal, HER2+, triple negative).10
1.5 Definitions
•

BI-RADS Mammographic Assessment Categories:31
o

Category 0: Incomplete/indeterminate – recalled for additional imaging

o

Category 1: Negative
5

•

o

Category 2: Benign

o

Category 3: Probably Benign

o

Category 4: Suspicious for Malignancy

o

Category 5: Highly Suggestive of Malignancy

BI-RADS Description of Overall Breast Composition:31
o Category A: Breasts are predominantly fatty
o Category B: There are scattered areas of fibroglandular density in the breasts
o Category C: Breasts are heterogeneously dense; this may obscure small masses
o Category D: Breasts are extremely dense; this lowers mammographic sensitivity

•

Nuclear Grade (for in situ cancers):37
o Grade 1 (Low): Well-differentiated cells; tend to grow slowly
o Grade 2 (Intermediate): Moderately-differentiated cells
o Grade 3 (High): Poorly-differentiated cells; tend to proliferate quickly

•

Nottingham Histologic Grade (for invasive cancers):38
o

Grade 1: Well-differentiated malignant cells; 95% 5-year survival

o

Grade 2: Moderately-differentiated malignant cells

o

Grade 3: Poorly-differentiated malignant cells; 50% 5-year survival

Operational Definitions:
•

BI-RADS 0 cases: Refers to women recalled after screening mammography (DBT or
FFDM) for additional imaging.

•

Digital Breast Tomosynthesis (DBT): In this study, DBT refers to tomosynthesis
adjunct to full-field digital mammography; unless otherwise specified, DBT refers to
DBT+FFDM.
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CHAPTER II: REVIEW OF THE LITERATURE
2.1 Introduction
2.1.1 Literature Search
Literature was reviewed by means of PubMed between August 2016 and July 2017.
All articles were published after 2007. A final search was completed on July 16, 2017.
Key terms for digital breast tomosynthesis (DBT) included tomosynth*, 3D
mammography, 3-D mammography, three dimensional mammography, and threedimensional mammography. The MeSH term Breast Neoplasm indexed all search criteria
for breast cancer. Key terms for BI-RADS 0 cases (women recalled from screening for
further imaging) included BIRADS 0, BI-RADS 0, and recall. Categories were combined
using and/or functionalities. Literature returned from the initial search (n=62) included
retrospective studies, prospective studies, and systematic reviews. International articles
were included in the review, but the search was narrowed to the English language only.
The review was further limited to humans (species), female (sex), and last 10 years
(publication dates), returning 59 articles. Three additional full-text articles were assessed
after citation searches. Studies evaluating any of the following were excluded: women
with previous diagnoses/treatment of breast cancer; women with breast cancer
signs/symptoms; diagnostic/non-screening settings; one-view DBT; assessment of DBT
for technological development; and review articles. Studies with fewer than 300
participants were also excluded. After full-text screening (n=62), 42 articles were
excluded: eighteen reviews; ten diagnostic/non-screening studies; six technical studies;
six studies assessing different DBT protocols; one study assessing women with prior
history of breast cancer; and one study with fewer than 300 participants, resulting in
review of twenty original reports (Figure 1).
10

Figure 1. Literature Review Flow Diagram
2.1.2 Digital Breast Tomosynthesis
Mammography screening with two-dimensional (2D) full-field digital mammography
(FFDM) has been shown to decrease mortality from breast cancer by 30% or more due to
earlier detection.1 Despite this achievement, tissue overlap observed in 2D images
acquired with FFDM creates significant obstacles for interpretation.2 Overall, FFDM has
low sensitivity and specificity, leading to false positive recalls and unnecessary additional
workup – particularly in women with dense breast parenchyma due to the masking effect
of overlapping breast tissue.3
Digital breast tomosynthesis (DBT) is a form of mammography that produces quasi
three-dimensional (3D) images of the breast via acquisition of a series of low dose
images obtained over a limited arc, which are then reconstructed and displayed in small
11

(1 mm) image slices.4 DBT images are displayed in combination with standard FFDM 2D
images – or, more recently, synthetically reconstructed 2D images from the DBT data.4
DBT provides greater imaging detail and addresses the challenges presented by
overlapping breast tissue observed in FFDM, such as the concealment of true malignancy
and the mimicry of cancer.5
As discussed in the following sections, several studies have reported significant
increases in overall and invasive cancer detection rate (CDR), with no change in the in
situ CDR, with the addition of DBT to screening. This has important implications, as the
treatment of in situ carcinomas – specifically, ductal carcinoma in situ (DCIS) – is a
highly controversial and heavily debated topic, with major concerns regarding overdiagnosis and overtreatment.6 Studies assessing population screening with DBT have also
reported significant reductions in recall rate (RR), in addition to an increase in positive
predictive value from recall (PPV1) with DBT versus FFDM alone, suggesting that a
positive DBT screening examination is more likely to truly detect cancer.
This review will appraise prior research assessing population-based screening with
DBT versus FFDM alone, with specific focus on studies that evaluate screening
outcomes, including PPV1, and detail the characteristics of tumors detected with DBT.
2.2 Review of European Studies
It is important to note some vital differences between screening studies performed in
the United States and those performed in Europe. In Europe, screening mammography is
performed under a double-reading protocol in which two radiologists independently
review examinations; in the United States, screening interpretation is performed by a
single radiologist.7 Other distinctions involve breast cancer rates (higher in the US than in
12

Europe) and population demographics.8 We will briefly review the major findings from
two prospective European population screening studies comprising five reports: the
STORM trial from Italy (two reports) and the OTST study from Norway (three reports).
2.2.1 STORM: Italy
The principal publication for the Screening with Tomosynthesis OR standard
Mammography (STORM) trial comes out of two centers in Italy. STORM prospectively
compared the CDR, RR, and false positive recall rate in asymptomatic women 48 years
or older (n=7,292; median age 59 years, IQR 48-71) who presented for population-based
screening from 2011 to 2012. Each participant underwent two-view craniocaudal (CC)
and mediolateral oblique (MLO) screening mammography with FFDM (phase 1)
followed by DBT (dual-acquisition DBT+FFDM, phase 2). Images were reviewed per a
double-reading protocol in which two radiologists independently assessed screening
mammography exams, as is common practice in Europe. In STORM, images were
reviewed in a sequential order by the two radiologists in parallel: in phase 1, 2D images
from FFDM were evaluated, and each radiologist independently determined if the
participant should be recalled based on those images alone. Regardless of that decision,
the same two radiologists then independently reviewed the 3D images from the DBT scan
later that day (phase 2), and again decided if the participant should be recalled. If either
of the two radiologists decided to recall the patient at either of the two phases, the patient
was recalled and the examination was considered to be a positive screen.9
Outcomes involved comparison of the number of cancers and false positive recalls
from FFDM only (phase 1) versus the number of cancers and false positive recalls from
DBT (phase 2). The authors additionally applied a conditional recall rule, whereby recall
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was restricted to positive DBT screens only (phase 2), excluding FFDM-only positive
screens (phase 1), in order to determine the incremental cancer detection rate attributable
to DBT and to better estimate the false positive recall rate from DBT.9
Overall, 59 cancers were detected: 39 (66%) were seen with FFDM (phase 1) for a
FFDM CDR of 5.3 per 1000 screened, while all 59 were seen on DBT+FFDM (phase 2)
for a DBT CDR of 8.1 per 1000 screened (p<0.0001). Twenty cancers that were seen
with dual-acquisition DBT were not visible on FFDM, indicating an incremental CDR of
+2.8 per 1000 screened, or a 53% relative increase in CDR attributable to dualacquisition DBT. Of the 59 cancers detected, 52 (88%) were invasive: 35 were detected
on both FFDM (phase 1) and DBT (phase 2), while 17 were detected only with DBT
(phase 2), yielding a FFDM invasive CDR of 4.8 per 1000 screened and a DBT invasive
CDR of 7.1 per 1000 screened (p<0.0001), resulting in a 49% increase in the invasive
CDR attributable to DBT. With the application of the conditional recall rule, the false
positive recall rate was 5.5% for FFDM versus 3.5% for DBT (p<0.0001), resulting in a
17% reduction in the false positive recall rate attributable to DBT.9 A secondary
retrospective analysis of STORM revealed that there were no significant differences in
outcome measures across the two screening centers, Trento and Verona.10
Six interval cancers – defined as cancers diagnosed after a negative mammography
screening examination but before the next routine screen – were observed in first-year
follow-up from STORM. From the 59 cancers noted in the principal STORM report and
the additional six interval cancers from first-year follow-up, the authors calculated the
incremental CDR attributable to the addition of DBT using retrospective models of both
single-reading and double-reading methods for the 65 cancer cases. For the single14

reading strategy, 35 cancers were detected at both FFDM and DBT (phases 1 and 2);
twenty detected only with DBT (phase 2); and none detected on FFDM alone (p<0.001).
Ten cancers were not detected. For the double-reading strategy, 39 cancers were detected
with both FFDM and DBT (phases 1 and 2); twenty detected only with DBT (phase 2);
and none detected with FFDM alone (p<0.001). Six cancers were not detected.
Regardless of reading strategy (single or double), the incremental CDR from the addition
of DBT was +2.7 per 1000 screened (p<0.001).11
The authors additionally assessed five different strategies to minimize the false
positive to true positive (FP:TP) ratio – the number of false positive recalls per true
positive screen-detected breast cancers. Thus, this ratio is a measure of specificity. For
both reading methods, it was determined that strategies using DBT with conditional recall
yielded the highest sensitivities and lowest FP:TP ratios (highest specificities). For the
single-reading method, sensitivity was 85%, with a FP:TP ratio of 3.7, and for the
double-reading method, sensitivity was 91% with a FP:TP ratio of 4.3. When using a
single-reading strategy without the conditional recall rule – the strategy most similar to
screening protocols performed in the US – the sensitivity from DBT was 85% versus
54% for FFDM alone. While not explicitly reported in this report, the specificity, PPV1,
and negative predictive value (NPV1) from recall have been calculated by means of twoby-two tables using data from the single-reading strategy for FFDM alone versus DBT
(Table 1). While specificity and NPV1 were nearly equal for DBT versus FFDM alone –
97% versus 96%, and 99.9% versus. 99.6%, respectively – there was a significant
increase in sensitivity (85% versus 54%) and PPV1 (21.2% versus 11.4%) with DBT
versus FFDM alone, respectively.11
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Table 1. STORM: Single-Reading for FFDM and DBT
Disease Status

FFDM
Test Results

FFDM +
FFDM Total

DBT

Cancer +
35
30
65
Sensitivity: 54%

Cancer 272
6,956
7,228
Specificity: 96%

Total
307
6,986
7,293

PPV1: 11.4%
NPV1: 99.6%

Disease Status

Cancer +
Cancer Total
DBT +
55
204
259
PPV1: 21.2%
Test Results
DBT 10
7,024
7,034 NPV1: 99.8%
Total
65
7,228
7,293
Sensitivity: 85%
Specificity: 97%
Sensitivity was reported by Houssami et al.11; Specificity, Positive Predictive Value from recall (PPV1) and
Negative Predictive Value from recall (NPV1) were calculated for this review.

The results from the STORM reports suggest that the overall and invasive CDR
increase significantly with the addition of DBT to screening, with no change in the
detection of in situ cancers. Furthermore, there were significant reductions in both recall
rate and false positive recalls from screening with DBT versus FFDM alone. DBT
enhanced sensitivity and PPV1, without compromising specificity and NPV1. It should be
noted that the 54% sensitivity detected for FFDM is considerably lower than the
sensitivity of FFDM observed in the US.1 In practice, these findings translate to a
decrease in recall rate, plausibly as a result of the significant reduction in false positive
recalls; an increase in true positive recalls from screening; a higher likelihood that
women recalled from DBT screening will truly have cancer; and an increase in overall
and invasive cancer detection, with no change in the detection of in situ cancers.
2.2.2 OTST: Norway
The Oslo Tomosynthesis Screening Trial (OTST) out of Norway prospectively
compared two-view (CC and MLO) screening with DBT versus FFDM alone. Norwegian
women 50-69 years of age were sent letters to participate in the trial, which ran from
November 2010 through December 2011. Women scheduled for a screening examination
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were asked upon arrival if they were willing to participate in the trial, pending the
availability of technical staff and necessary imaging systems. Women who were not
asked to participate in the trial due to lack of available resources were screened with
standard two-view FFDM. Women who were unable to stand and women with breast
implants were excluded from the trial. Overall, 12,621 women (average age: 59.3 years)
were included in the trial.12
A problem posed by independent double-reading without consensus of management
decisions is the substantial increase in recall rate.12 While OTST utilized a four-arm
prospective independent double-reading design, they also employed an arbitration
process for double-reading prior to recalling patients, in contrast to STORM. Study arms
included: Arm A, FFDM alone (2D data); Arm B, FFDM with computer-aided detection
(CAD; 2D data), a software feature that augments FFDM lesion detection; Arm C,
FFDM+DBT (2D+3D data); Arm D, synthetic-2D+DBT (2D+3D data). Eight
radiologists participated in the study, alternating across the four arms. Because of the
double-reading design, each arm was independently assessed and rated by one of four
radiologists using the following standardized five-point rating scale: 1=Normal/definitely
benign; 2=Probably benign; 3=Indeterminate; 4=Probably malignant; 5=Malignant. A
consensus meeting was called for cases with any score of 2 or greater, involving at least
two radiologists, allowing for discussion and assent of the clinical management decision
to either recall or dismiss patients with at least one rating of 2 or 3; conversely, any
woman with at least one score of 4 or 5 was automatically recalled and could not be
dismissed at consensus. It should be noted that any screening examination rated ≥2 by at
least one radiologist was considered to be a positive examination (pre-arbitration
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suspicion), regardless of the consensus decision to dismiss or recall. For analyses, it was
assumed that Arm A was equal to Arm B, and Arm C was equal to Arm D – in other
words, the 2D paired arms (A and B) and the 2D+3D paired arms (C and D) were
sufficiently similar such that independent reading of Arm A + Arm B constituted doublereading for 2D images, and independent reading of Arm C + Arm D served as doublereading for 2D+3D exams.12 Of the 29 additional cancers detected under the 2D+3D
mode (and undetected on 2D-alone mode), 24 (82.8%) were invasive, node-negative
cancers. Although 2D-based imaging alone missed cancers across all four categories of
breast density, the added benefits of 2D+3D (DBT) for screening most significantly
improved outcomes in women with BI-RADS breast density categories B and C
(scattered fibroglandular densities and heterogeneously dense breasts). There was no
significant difference in the in situ (DCIS) CDR across modalities.12
A more applicable understanding of the OTST study comes from the pre-planned
single-reading interim analysis of OTST, evaluating two of the four OTST arms: FFDM
alone versus dual acquisition DBT. At the time of the publication, the authors reported a
significantly higher CDR (27% increase, p=0.001); a significantly higher invasive CDR
(40% increase, p<0.001); no significant difference in DCIS detection; and a significant
15% reduction in false positive recall rates (p<0.001) with DBT versus FFDM alone.13
The prospective European studies discussed in this review, STORM and OTST, have
important strengths and limitations. Strengths include paired data and prospective study
design, a powerful strategy for assessing incidence and causality. Weaknesses include
lack of generalizability and limited applicability to US populations due to differences in
disease prevalence, population demographics, and screening practices.
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2.3 Review of United States Studies
The United States (US)-based studies are inherently more relevant to our proposed
study in terms of design, demographics, and screening protocols/practices. Thus, the
majority of our study methods (Chapter III) have been derived from these reports.
Study characteristics from the fourteen US reports reviewed in this chapter have been
summarized in Table 5 (Appendix A, pp. 59-60). Reports include eleven retrospective
reports, two hybrid prospective/retrospective cohort studies, and one prospective study.
The major outcomes for each study have been comprehensively summarized in Table 6
(Appendix A, pp. 61-63). The ensuing discussion revolves around the study designs and
specific outcomes found in the accompanying tables; thus, the reader is encouraged to
utilize these resources throughout this section.
All but one of the fourteen US studies reviewed in this chapter employed
independent, single-reading interpretations of images with two-view (CC and MLO)
bilateral image acquisition for both FFDM and DBT screening, as is standard practice in
the United States. A sole publication by Destounis et al. (2014) interpreted screening
examinations under a double-reading protocol.
2.3.1 Initial Studies
In 2013, Rose et al. published a single-site retrospective study comparing 23,355
asymptomatic women 18 years and older who presented for screening both before and
after a distinct FFDM-to-DBT transition period. Women who were screened with FFDM
after the transition period were excluded from analyses, although most (88%) of women
presenting for screening after this time elected for screening with DBT. Because the site’s
radiologists had varying degrees of DBT experience, the authors decided to include only
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cases evaluated by radiologists who had assessed at least 500 cases pre- and post-DBT
implementation. Thus, the study’s sample size was derived from cases interpreted by six
radiologists meeting these qualifications. A priori, a generalized linear model was
prepared to compare outcomes across DBT and FFDM after adjusting for age at
screening, baseline exams, and individual radiologists’ performance via random-reader
assumption. Outcomes were stratified by BI-RADS breast density categories (A, B, C,
and D) and age at screening (<50 years; 50-64 years; and >64 years).14
Overall, Rose et al. (2013) reported a significant 37% reduction in recall rate and an
115% increase in PPV1 with DBT versus FFDM alone, in addition to non-significant
increases in the overall and invasive CDR – trends that reflected findings observed in the
prospective European trials. Of note, the improved performance metrics observed with
DBT were significant across all age groups and breast density subgroups, with the largest
gains for women presenting for baseline (first ever) exams. These findings highlight the
benefits gained by the addition of DBT to screening, such as enhanced cancer detection,
in addition to the abatement of harms, as evidenced by lower recall rate and higher
likelihood that recall from DBT screening results in a diagnosis of cancer, ultimately
leading to fewer false positive recalls, unnecessary workups, and benign biopsies.14
Rose et al. (2014) sought to validate the improved performance metrics observed in
their principal 2013 report. The authors subsequently published an independent reading
study retrospectively interpreting FFDM screens acquired during dual acquisition DBT
during the previously reported DBT time period.14 These screening outcomes were then
compared to the outcomes from the corresponding, prospectively interpreted DBT exams
published in the 2013 publication; thus, all data were paired across modalities. In the
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2013 report, 10,878 DBT screens from asymptomatic women were prospectively
interpreted by ten radiologists, with seven radiologists now participating in the
retrospective interpretation of the paired FFDM images for the 2014 study – most of
whom had limited experience with DBT at the beginning of DBT transition period.
Radiologists involved in the retrospective interpretation of FFDM screens were assigned
by a third party to cases that they had not personally interpreted in clinic, and were
blinded to the true clinical recommendations and associated outcomes. All retrospective
FFDM cases rated as BI-RADS 0 (recommendation of recall) were reviewed by an
independent third radiologist who had not been involved in the interpretation of the
patient’s screening examinations.15
Outcomes for recall rate were much the same as reported in the authors’ 2013
publication, with a significant reduction of 33.7%. Overall and invasive CDR increased
significantly with DBT versus FFDM alone – 54.3% and 63%, respectively – with no
significant difference in the in situ CDR across modalities.15 These findings lent credence
to the authors’ 2013 findings, and suggested that the previously observed non-significant
increases in the overall and invasive CDR were likely limitations of the former report’s
design and sample size, with the latter report finding these outcomes to be significant.
Limitations of Rose et al.’s 2013 report include its retrospective nature, nonrandomization of patients, and lack of power to detect significant changes in cancer
detection due to the relatively small sample size. Furthermore, because women had to
elect to undergo screening with DBT, self-selection bias cannot be ruled out or easily
accounted for. The authors also noted that the effects of learning this new technology
were difficult to quantify, though they expected that performance metrics were not likely
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to have increased substantially over the short duration of the study. The 2013 study
would have additionally benefited from more detailed baseline characterization across
modalities to compare important and potentially confounding factors, such as race,
ethnicity, and personal/family history of breast cancer. In the 2014 report, however, the
use of paired data eliminated potential differences in disease prevalence and baseline
characteristics across groups.
In 2013, Haas et al. published a retrospective study comparing 13,158 women
presenting for screening mammography with DBT versus FFDM alone at one of four
sites affiliated with Yale University. DBT screening was offered where and when it was
available to consenting women at no additional cost. Women with breast implants or
large breasts requiring tiled images were excluded from DBT. Per modality, recall rate
was calculated by dividing the number of BI-RADS 0 women by the total number
screened, and CDR was evaluated by determining the number of true positive BI-RADS
0 cases per 1000 women screened. Recall rate and CDR (overall, invasive, in situ) were
additionally stratified by patient age at screening and breast density categories. A priori,
the authors planned to utilize multivariate logistic regression analysis to determine any
significant differences in CDRs and recall rates across modalities after controlling for
patient age at screening (<40; 40-49; 50-59; 60-69; ≥70 years), BI-RADS breast density
categories (A, B, C, D), and the presence of a personal history of breast cancer and/or
family history of breast cancer in a first-degree relative.16
Comparison of baseline population characteristics revealed similarities in breast
densities and ages across the two groups, but found that patients in the DBT group were
more likely to have a personal history and family history of breast cancer as compared to
22

the FFDM group. A statistically significant reduction in recall rate of 30% was observed
in women screened with DBT versus FFDM alone. Stratification by breast density
revealed recall rate reduction for all subgroups, with significance observed for BI-RADS
categories B, C, and D. Stratification by age demonstrated recall rate reduction for all
ages, with significance seen in all groups except for women 70 years of age or older.
These outcomes, reported as odds of recall, persisted after multivariate logistic regression
analyses, with greatest reductions seen for women younger than 40 years old and women
with BI-RADS breast density category D. Multivariate adjustment for age, breast density,
and the presence of personal and/or family history (or absence of both) revealed a 38%
reduction in odds of recall from DBT versus FFDM alone. The authors found age and
breast density to be independent predictors for risk of recall. There was a slight, albeit
non-significant, 9.6% increase in the overall CDR and 11.4% increase in the invasive
CDR with DBT versus FFDM alone, with no change in the in situ CDR.16
Durand et al. expanded upon the above cohort in their 2015 publication, comparing
outcomes from 17,955 women (including the 13,158 cases from Haas et al.’s 2013 report)
screened with DBT versus FFDM.17 In addition to retrospectively comparing overall
recall rates and cancer detection rates across the two modalities, the authors compared
recall rates for baseline examinations across the two modalities, a population previously
shown to derive benefit from screening with DBT, appreciation recall rate reduction and
increased cancer detection rates, as compared to FFDM.14 In contrast to Haas et al.’s
2013 report, in which the only baseline difference across groups was the significantly
higher proportion of women in the DBT group with risk factors, Durand et al. (2014)
observed significant differences across all baseline measures: risk factors, age at
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screening, breast density, and number of women presenting for baseline examinations
(p<0.0001). However, the significant 36.6% recall rate reduction with DBT versus FFDM
alone substantiated the 2013 findings by Haas et al. After adjusting for confounding
factors, the odds of recall from FFDM were found to be 1.76 times higher than DBT.
Similarly, for baseline examinations, recall rate was significantly reduced by 37%
(p<0.0001). Non-significant increases of 3.5% and 8.8% were observed in the overall and
invasive CDR, respectively, with no change in the in situ CDR across modalities.17
In their 2013 report, Haas et al. speculated that the true differences in CDR across the
two modalities may have been greater than what was observed due to a confounding
effect through use of DBT in the diagnostic environment at one of the four sites;
consequently, women recalled from the FFDM group may have benefited from cancer
detection with diagnostic DBT, falsely elevating the CDR from FFDM.16 If accurate, this
would have similarly affected the CDRs in Durand et al.’s 2015 publication. Regardless,
both publications were underpowered to detect significant changes in cancer detection.
Due to the discrepancies in DBT screening capability across sites in these two reports,
outcomes may have been affected by selection bias due to potential differences in
populations presenting to sites that both did and did not offer DBT as a screening option.
The observed dissimilarity in baseline screening characteristics suggest that this is a
possibility; in the 2013 report, significantly more women in the DBT group had a
personal and/or family history of breast cancer, a population that is inherently at higher
risk of developing breast cancer. Therefore, it is not outside the realm of reason to
presume that such a population might be recalled from screening at a higher rate than the
general population. Yet, despite the fact that the DBT group contained proportionally
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more high-risk women than the FFDM group, a statistically significant reduction in recall
rate was observed across the two modalities.16,17 In the 2015 report, baseline
characteristics across modalities further diverged, with significant dissimilarity in risk
factors, age, breast density, and number of baseline examinations performed.
Furthermore, the observed differences in risk factors across groups were split: the
proportion of women with a strong or intermediate family history was significantly
higher in the FFDM group than in the DBT group, while the proportion of women with a
personal history of breast cancer was significantly higher in the DBT group than in the
FFDM group.17 Nevertheless, after adjusting for confounding factors, the odds of recall
were still significantly lower for DBT versus FFDM.
2.3.2 Subgroup Benefits
Logistic regression analyses in the 2013 report by Haas et al. revealed that the women
who derived the greatest benefit from the addition of DBT to screening examinations
included those with dense breasts and/or those younger than 50 years of age; precisely the
populations in which FFDM alone is least effective.16 The 2015 publication by Durand et
al. substantiated previous evidence published by Rose et al. (2013) suggesting that
women presenting for baseline examinations derived significant benefits from screening
with DBT versus FFDM alone by means of recall rate reduction.14 The outcomes from
the reports by Rose et al. (2013, 2014), Haas et al. (2013), and Durand et al. (2015)
converge when considering the fact that younger women – a population with inherently
higher breast density – are likely to constitute a significant proportion of women
presenting for baseline screening examinations. As discussed below, several other studies
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found significant benefits in specific populations from DBT screening, including young
women presenting for baseline examinations.18-21
McCarthy et al. (2014), in their single-site retrospective study (n=26,299) comparing
women screened with FFDM versus DBT, found non-significant increases of 19.6% and
22% in the overall and invasive CDR, respectively, with no change in the in situ CDR.
When stratified by age, the CDR increased a significant 159% in women under 50 years
of age screened with DBT versus FFDM alone. The overall recall rate was significantly
decreased by 15.4% with DBT versus FFDM; significance persisted with univariate and
multivariate adjustment for number of screening rounds, age, race, interpreting
radiologist, and presence or absence of a prior mammogram, with reduced odds of recall
for women screened with DBT versus FFDM. With multivariate adjustment, the odds of
recall were 20% lower from DBT than from FFDM alone.18
Other subgroups significantly benefited from screening with DBT versus FFDM after
multivariate adjustment. The odds of recall for FFDM versus DBT were highest for
women presenting for baseline screening exam (adjusted OR=2.31; 95% CI: 2.04-2.61,
p<0.001); younger women, ages 40-49 years (adjusted OR=1.85; 95% CI: 1.56-2.19,
p<0.001) and 50-59 years (adjusted OR=1.41; 95% CI: 1.19-1.67, p<0.001); and black
women (adjusted OR: 1.14; 95% CI: 1.04-1.26, p=0.008). Simply put, women with no
prior mammograms (baseline examinations) had >2.5 times higher odds of recall than
women with a prior mammogram; women age 40-49 and 50-59 years had 85% and 41%
higher odds of recall, respectively, compared to women ≥70 years (referent age group);
and black women had 14% higher odds of recall compared to white women. Further
multivariable adjustment was performed in a random subset of the population (58% of
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the total sample), including additional risk factors for breast cancer (Appendix F). From
this adjustment model, there was a significant 23% decrease in the odds of recall from
DBT versus FFDM alone (adjusted OR=0.77; 95% CI: 0.68-0.87, p<0.001). Stratification
of recall rates by breast density revealed significant decreases with DBT versus FFDM in
both non-dense breasts (BI-RADS categories A and B; 14.3% reduction, p=0.001) and
dense breasts (BI-RADS categories C and D; 16.5% reduction, p=0.006). The positive
predictive value from recall (PPV1) significantly increased by 41% with DBT versus
FFDM alone; when stratified by age, this value was a significant 17.5% higher in women
under 50 years of age screened with DBT versus FFDM alone.18
McDonald et al.’s 2015 report is from the same population of 26,299 women as
reported above. However, in attempt to better delineate the effectiveness of DBT in
women with no previous screening mammography exams, the population was stratified
into two cohorts across the FFDM and DBT time periods: a baseline subgroup (women
with no prior mammograms) of 3,063 women and a previously-screened group, the vast
majority of the population, comprising 23,236 women. Unsurprisingly, women in the
baseline subgroup were, on average, nine years younger than women in the previouslyscreened group. The mean age was similar across modalities for both subgroups.19
The analyses focused primarily on the baseline subgroup, and found a significant
recall rate reduction of 22% with DBT versus FFDM alone. Within the baseline
subgroup, there was a significant 24.1% reduction in recall rate for women under 50
years of age with DBT versus FFDM alone. A significant (p=0.004) recall rate reduction
of 24.1% was similarly observed in baseline women with non-dense breasts (BI-RADS
categories A and B). Women with dense breasts (BI-RADS categories C and D) had a
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non-significant 17.2% recall rate reduction (p=0.14) from DBT versus FFDM.
Multivariate logistic regression analysis of recall rate (adjusting for breast density BIRADS categories; age; race; and interpreting radiologist) resulted in significant decreases
in odds of recall from DBT versus FFDM for both subgroups: 16% lower odds of recall
in the previously-screened group, and 26% lower odds of recall in the baseline subgroup.
The PPV1 increased a non-significant 85% in the baseline subgroup and a significant
35.3% in the previously-screened group. Multivariate logistic regression analysis of PPV1
(adjusting for age and breast density) was significant only in the previously-screened
group, revealing a 57% increased odds of cancer detection in cases recalled from DBT
versus FFDM. In the baseline subgroup, the odds of cancer detection from recall were
81% higher with DBT versus FFDM, but this was a non-significant finding.19
Strengths of the reports by McCarthy et al. (2014) and McDonald et al. (2015)
include a swift DBT transition period of one month, and the exclusion of data acquired
during this period further limited the possibility of selection bias. The same six
radiologists interpreted all images pre- and post-DBT implementation. In the 2014 report
by McDonald et al., the authors were able to assess several additional breast cancer risk
factors that had not yet been reported in the screening population. Limitations of these
studies, aside from their retrospective design, include significant disparity in distribution
of baseline characteristics across women screened per imaging modality: in the DBT
group, there were proportionally fewer black patients; proportionally more women
categorized as BI-RADS A; and proportionally fewer patients who were previously
screened. These differences were, however, accounted for in multivariate logistic
regression analyses.18
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In 2015, Sumkin et al. published a small, single-site prospective cohort study
specifically comparing paired DBT and FFDM data in young asymptomatic women (ages
34-56 years) presenting for baseline screening examinations (n=1,074).20 The only
outcome of interest was recall rate, which tends to be higher in the population of interest,
as noted by several studies discussed thus far.14,16-19 Each participant was imaged with
FFDM and dual acquisition DBT, and the two exams were independently reviewed in
clinic by two of fourteen participating radiologists. By design, the authors included no
consensus process to best model US screening practice. Therefore, a participant was
recalled if either (or both) of the two independent radiologists assigned a BI-RADS 0
designation from either the FFDM-only or DBT exam. Recommended recalls were
analyzed using a generalized linear mixed model for binary data in consideration of a
possible correlation between exam interpretations of an individual patient and the
variability of individual radiologists’ performance per modality. Because of the split
nature of the study (two exams under two reading modes by two radiologists), a twosided p value of 0.0294 was used to test for significance. The recommendation for recall
was significantly decreased by 33.6% with DBT versus FFDM alone (p<0.001). The false
positive rate was found to be 16.4% after 176 women without breast cancer were recalled
by both DBT and FFDM. Overall, in addition to a significant reduction in recall rate, the
authors observed a notable decrease in benign biopsies performed with use of DBT,
contributing to the evidence supporting the role of DBT in harm reduction from screening
mammography.20
Strengths of this study include the prospective design, allowing for causal inference,
and the use of paired data, eliminating differences across groups. The generalizability of
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this study is limited, as it was performed out of a single institution and evaluated a small,
specific group of women. Self-selection bias cannot be ruled out, especially because high
risk women were recruited. Cancer prevalence is low in this age range (34-56 years),20
and the sample size was significantly underpowered to detect significant changes in
cancer detection; thus, comparison of CDR across modalities was not possible.
Sharpe et al. (2016) published a single-site prospective study of DBT examinations
(n=5,703) with retrospective comparison of FFDM images (n=80,149) from a total of
85,852 asymptomatic women with no breast symptoms or diagnosis of breast cancer
within five years of the study. Recall rates were calculated for the two exams overall and
stratified according to patient age at screening; breast density; family history and personal
history of breast cancer; history of BRCA gene mutation; personal history of benign
breast biopsy; whether or not it was the patient’s first mammographic examination; and
interpreting radiologist. A mixed-effects logistic regression analysis was performed to
determine the correlation between each parameter and the recall rate.21
Outcomes demonstrated a significant 54.3% increase in the overall CDR (including a
153% increase in the in situ CDR); a significant 18.8% reduction in recall rate, with
significant subgroup benefit seen in women with BI-RADS categories C and D, and
women ages 40-49 or 60-69 years with DBT versus FFDM alone.21 The authors offered
no plausible basis for the lack of significant recall rate reduction in the 50-59-year age
group. Given the differences in baseline characteristics – namely, increased prevalence of
women with risk factors for breast cancer in the DBT group – self-selection bias is a
reasonable concern, and may have affected the observed differences in RR and CDR
across modalities. This suspicion is heightened in light of detecting an increased overall
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and in situ CDR, despite being significantly underpowered to do so. Because no other
study has observed a statistically significant increase in the in situ CDR from screening
with DBT versus FFDM alone, this finding likely represents an outlier.
2.3.3 Large Multisite Studies
The largest US study to date is a retrospective, multicenter, multisite trial by
Friedewald et al. (2014), encompassing thirteen sites and a sample size of 454,850 exams
from asymptomatic women presenting for screening mammography. The study was
designed to detect changes in CDR and RR with power of 80% and >99%, respectively.
All participating sites were in the process of transitioning from FFDM to DBT for
screening, though this process differed across sites. Women presenting pre-transition
period were screened with standard FFDM; those presenting post-transition were
screened with DBT. Because sites contributed varying numbers of participants overall
and per modality, outcomes were model-adjusted to account for site as a random effect.22
Results revealed a significant recall rate reduction of 15%; significant increases of
28.6% and 41.4% in the overall and invasive CDR, respectively, with no change in the in
situ CDR. Of note, per 1000 women screened, DBT detected significantly more invasive
ductal carcinomas (IDC; 33% increase) and invasive lobular carcinomas (ILC; 103.7%
increase), the most and second most common types of invasive breast cancers,
respectively.23 There was a significant 48.8% increase in PPV1 with DBT versus FFDM.22
Outcomes from this major study were consistent with findings from the smaller US
studies, in addition to the prospective European trials. This is noteworthy considering the
international differences in screening practices and patient demographics. Furthermore,
the thirteen sites included in the meta-analyses represent geographically diverse,
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academic and non-academic settings, encompassing both specially trained radiologists
and non-specialists. For these reasons, outcomes from this study are more generalizable
to the US population at large than many smaller, single-site retrospective studies.
This study was limited to population-level data, so adjustments were not possible for
women with repeat examinations. Differences in age at screening, breast density
categories, race/ethnicity, and risk factors were not described in the baseline populations.
Site differences in FFDM-to-DBT conversion times were not a consideration in the
adjustment model, nor were individual radiologists’ performance metrics. Only two sites
made a full transition, with the remaining sites operating as hybrid environments.
Because most sites concurrently offered both DBT and FFDM screening throughout the
study period, the authors were unable to rule out selection bias. FFDM-only screening
examinations performed in the DBT period were excluded from the primary analyses.
However, to address the lingering possibility of selection bias, analyses were repeated
with the inclusion of the concurrent FFDM-only examinations in the DBT group to test
for significant changes in CDR and RR pre- and post-DBT implementation. Outcomes
did not change significantly when such cases were added, despite the fact that nearly 60%
of screening exams were acquired with FFDM in the DBT study period.22 Lastly, because
women could decline DBT and opt for FFDM screening, self-selection bias is a potential
confounding factor that is difficult to address (i.e., women with known risk factors might
be more likely to elect for DBT screening).
That same year, Greenberg et al. (2014) published a smaller, albeit well-powered
multisite retrospective study comparing screening outcomes in 59,617 women presenting
for screening mammography performed with DBT versus FFDM alone. Only cases read
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by one of fourteen radiologists who had interpreted more than 500 DBT images during
the study period were included in analyses due to discrepancies in experience across
radiologists. It is worth noting that, of the 77,833 women screened, only 30% elected for
screening with DBT, while 70% opted for FFDM – possibly due to selection bias from a
$50 fee for screening with DBT, though this cost was waived if a participant could not
afford to pay. Despite the disparity in women who opted for screening with FFDM in lieu
of DBT, there were no significant differences in baseline characteristics across groups. A
generalized linear mixed model (GLMM) was employed to account for individual
radiologists’ performance with random reader assumption; multiple screening rounds
were also evaluated, using individual patients as the unit of analysis.24
Outcomes revealed a significant recall rate reduction of 16% for DBT versus FFDM
alone, with significance persisting after application of the GLMM. The overall and
invasive CDR significantly increased 28.6% and 43.8%, respectively, for DBT versus
FFDM, with no significant change in the in situ CDR. A significant 43.8% gain in PPV1
was observed with DBT versus FFDM, with a yet higher estimated increase of 51.14%
from the GLMM. The authors also found a significant reduction in the number of
additional mammographic views obtained in women diagnosed with breast cancer after
recall from DBT versus FFDM alone: 74.1% of patients in the DBT group required two
or fewer views at recall, with 35.1% requiring no additional views; conversely, 51% of
women in the FFDM group required two or fewer views, with no additional views needed
for 6.3% (p<0.001).24 In accordance with the outcomes observed in the prospective
European trials and across several US studies, including a large US meta-analysis, these
findings provided further support for the role of DBT in both benefit gain and harm
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reduction from screening, evidencing enhanced efficiency at recall with fewer required
mammographic views leading to diagnosis and, therefore, minimizing radiation exposure.
2.3.4 Sustainability of Improved Outcomes
Studies discussed in the previous subsections largely represent outcomes from first
rounds of DBT screening in the United States, otherwise known as prevalence
screening.25 Generally, prevalence (first round) screening has higher rates of detection
than incidence (subsequent) screening, because the cancers detected in prevalence
screening are from the large pool of cancers that already exist in a given population.25 On
subsequent rounds, the cancers detected are, theoretically, incident cancers (new cancer
cases). To determine whether or not the enhanced performance of DBT screening is
sustainable, subsequent rounds of DBT screening (incidence rounds) must be compared
to prevalence data from the same population.26 Two 2016 publications sought to assess
the sustainability of improved outcomes from subsequent DBT screening.
Conant et al. (2016) retrospectively evaluated screening outcomes from asymptomatic
women 40-74 years of age screened with DBT versus FFDM. Participating women had
no known history of breast cancer and no breast imaging within three months of the
study. Screening was performed at three large academic research centers with several
sites, all transitioning from FFDM to DBT screening, though the conversion occurred at
different times and varying rates. Exams were limited to those read by radiologists who
had interpreted at least 50 DBT and 50 DM exams. By these criteria, 198,881 exams from
103,401 women were eligible for analyses; the baseline group included 45,049 women
with one exam, while the subsequent exam group comprised 29,041 women with two
prior exams and 29,311 women with three or more prior exams. A priori, the authors
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prepared a logistic regression model adjusting for research center, age at screening (4049; 50-59; 60-74 years), breast density (BI-RADS categories A, B, C, D), and first exam.
Recall rate was further adjusted for the interpreting radiologist in a conditional logistic
regression model. The primary outcomes were subject to a generalized estimating
equation (GEE) model accounting for potential correlation of screening exams within the
same individual, which yielded similar ORs and 95% CIs as the multivariate model.27
In all, outcomes from the subsequent (incidence) screening rounds in women with at
least one year of imaging follow-up followed trends in the established literature
(prevalence screens), with significant recall rate reduction without increase in false
negative rates; increased overall and invasive CDR; and enhanced PPV1. Furthermore,
there was a significant increase in specificity without diminished sensitivity. Lastly, after
adjusting for confounding variables, the authors found similar odds of recall for women
with both dense and non-dense breasts, as well as for women in both age groups,
suggesting that there is no particular advantage for benefits of DBT by age or density.27
Perhaps the most convincing data for the longitudinal effectiveness of DBT screening
comes from McDonald et al.’s 2016 publication comparing outcomes from four
consecutive years of screening in a large, urban academic center: one year of FFDM
(year 0; FFDM-0), followed by three years of screening post-DBT implementation (years
1-3; DBT-1, DBT-2, DBT-3). In all, the authors obtained screening outcomes from
44,468 screening exams attributable to 23,958 women with no history or clinical
signs/symptoms of breast cancer. At the population level, outcomes were assessed across
DBT years, and each DBT year was evaluated against FFDM-0 (the referent year);
outcomes were stratified according to breast density (non-dense: BI-RADS categories A
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and B versus dense: BI-RADS categories C and D) and age (<50 years versus ≥50 years).
To assess the effect of prevalence and incidence screening, RR and CDR were compared
at the most recent screening exam across women undergoing their first, second, or third
round of screening with DBT. The screening outcomes for groups of women with only
one, two, or three DBT screens were adjusted for age, race/ethnicity, breast density, and
the presence or absence of a prior mammogram to estimate the odds of recall. Analysis of
women with only one DBT screen was further confined to women with a prior FFDM
exam available. For individual-level analysis of recall rates across the four years, GEE
models with logistic regression were employed (adjusting for age, race/ethnicity, breast
density, and number of prior screens using individual patients as the units of analysis).28
At the population level, each DBT year showed significant recall rate reduction as
compared to FFDM-0, with no significant difference across DBT years despite slight
increases in RR each year. The overall and invasive CDR increased non-significantly
each year, and but not significantly different across DBT years or compared to the FFDM
CDR. The PPV1, continued to rise each year compared to FFDM-0, with a non-significant
41% increase in DBT-1; a significant 47.7% increase in DBT-2; and a significant 52.3%
increase in DBT-3. The PPV1 across DBT years did not differ significantly.28
For the assessment of DBT prevalence and incidence screening, women with only
one screen (prevalence exam), were compared to the group of women with two and three
screens (incidence exams). Recall rates continued to decline with increased number of
prior screens: recall rate was 13% for women with only one screen, 7.8% for two screens,
and 5.9% for three screens. As compared to the one-screen group, RR reductions were
significant (p<0.001) for women with two screens (OR=0.56; 95% CI: 0.51-0.63) and
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three screens (OR=0.42; 95% CI: 0.35-0.79); CDR was significantly lower for the twoscreen group (OR=0.55; 95% CI: 0.39-0.79, p<0.001), but was not significantly lower for
the three-screen group (OR=0.65; 95% CI: 0.41-1.02, p=0.06). When the one-screen
group was constrained to include only women with a prior FFDM exam available for
comparison, similar results were obtained. The PPV1 was significantly lower only when
comparing the restricted one-screen group to the two-screen group (p=0.028).28
This report established continued recall rate reduction from DBT screening with
subsequent screening rounds, with significant reductions each DBT year as compared to
the referent FFDM year, and no significant difference across DBT years. RR reduction
was amplified in women returning for second and third (incident) DBT screens. The CDR
was not significantly different across DBT years, and despite increases each year, was not
significantly higher as compared to FFDM, possibly due to the small sample size. The
PPV1 was significantly higher each DBT year as compared to FFDM, with no significant
difference across DBT years. Overall, the benefits from DBT screening seem to extend
beyond prevalence screening, and appear to be sustainable at the population level.
2.4 Tumor Characteristics
The findings from studies detailing the characteristics of screen-detected tumors are
summarized in two tables: European studies, Table 7 (Appendix B, p. 64) and US
studies, Table 8 (Appendix B, pp. 65-66). Discussion in the following subsections is
heavily derived from the outcomes found in these tables; thus, the reader is encouraged to
utilize these resources throughout this section. To enhance applicability to US data, the
information presented from the European trial, OTST, is derived from the single-reading
data. Information regarding tumor characteristics was not described separately in the
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single-reading mode of STORM. One additional study that has not yet been discussed is
included in the subsections below, for an aggregate review of seven reports.
Briefly, Wang et al. (2016) sought to characterize the biologic features of the
additional cancers detected with DBT versus FFDM alone, expanding upon Skaane et
al.’s 2013 interim OTST analysis, which revealed increased detection of primarily lowgrade, invasive, node-negative cancers with DBT, in contrast to no significant differences
observed by Greenberg et al. (2014). Sixty-five breast cancers detected in 63 women
undergoing first-ever screening (with DBT as the first exam) were retrospectively
interpreted by five radiologists, each independently evaluating FFDM versus DBT
images. A cancer was considered mammographically occult if all radiologists agreed that
the cancer was not visible on FFDM, for a total of ten cancers detected only with DBT.29
2.4.1 Tumor Size
Five studies published data on the sizes of cancers detected with DBT versus FFDM
alone, four of which included size information for invasive cancers only. In the STORM
trial, the mean size of invasive tumors was not significantly different for tumors detected
with DBT only (FFDM occult) compared to cancers detected with both FFDM and DBT.9
Rose et al. (2013) found that the sizes of invasive tumors did not differ significantly as
detected with DBT versus FFDM.14 Durand et al. (2015) did not provide mean or median
size values, but rather the pathologic size ranges of invasive tumors, reporting that the
majority of invasive cancers (75% of DBT-detected and 72% of FFDM-detected) fell in
the range of less than 2 cm across both modalities, with 25% of tumor sizes ranging from
2 to 5 cm with both DBT and FFDM alone.17 The OTST single-reading interim
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publication reported tumor size means, medians, and ranges for both invasive and in situ
cancers, with no significant differences across modalities noted for either.13
In the 2016 publication by Wang et al., nine of the ten cancers detected with DBT
only (FFDM occult) were invasive cancers. Compared to the 32 invasive cancers visible
on FFDM, the sizes of cancers detected with DBT only (FFDM occult) were smaller,
trending towards but not quite achieving significance (p=0.07).29
2.4.2 In Situ Cancers
Overwhelmingly, the data suggest that there is no increase in the in situ CDR from
screening with DBT compared to FFDM alone. Lower grade in situ cancers are generally
slower growing and have lower probability of progression and recurrence.30 After
stratifying screen-detected DCIS by nuclear grade, Greenberg et al. (2014) found that
DBT detected significantly more low- and intermediate-grade in situ cancers (67.6%)
than did FFDM (46.7%).24 Two other studies saw no significant difference in the
distribution of DCIS grades across modalities.13,14
2.4.3 Invasive Cancers
Six studies characterized the histologic types of invasive cancers detected with DBT
versus FFDM, and none reported significant differences in the proportions detected
across the modalities. Only one study reported the proportion of receptor phenotypes
(luminal, HER2-enriched, or triple negative) in invasive cancers, and found no significant
differences across modalities.9
The Nottingham histologic grade of invasive cancers has important implications for
prognosis and treatment.31 Greenberg et al. (2014) found no significant differences in the
proportions of invasive cancer grades detected across modalities.24 The cancer grades
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were similarly distributed in the prospective European trial, STORM.9 Rose et al.’s 2013
study reported no significant differences in the grades of invasive cancers nor the nuclear
grades of DCIS, but noted that more invasive cancers detected with FFDM alone were
grade 3, while more invasive cancers detected with DBT were grade 2.14 Skaane et al.’s
2013 interim OTST single-reading analysis found no significant difference in the
proportions of invasive cancer grades detected across modalities; however, when
evaluating the 29 additional cancers found only with adjunct DBT (FFDM occult), 48%
were grade 1, 39% grade 2, and only 10% grade 3.13 Wang et al. (2016) similarly found a
significant difference in the grades of DBT-detected (FFDM occult) invasive cancers as
compared to invasive cancers visible on FFDM, observing that 78% of DBT-only cancers
were grade 1 compared to 47% of FFDM-detected cancers, while 22% of DBT-only
cancers were grade 2 to 3 compared to 53% of FFDM-detected cancers.29
Perhaps the most significant prognostic factor for patients with early-stage breast
cancer is axillary lymph node status.31 Two screening studies found no difference in
lymph node status across modalities.14,17 Lymph node status was not significantly
different across modalities in STORM.9 As noted by the authors, one of the most
important findings from Skaane et al.’s 2013 interim OTST analysis was that the
additional cancers detected with DBT were primarily invasive and node-negative.13
Twenty-nine of the 30 additional cancers detected by DBT (FFDM occult) were invasive
(96.7%), and 80% of the invasive cancers were node negative.13 Wang et al. (2016) found
that, of the nine additional invasive cancers detected with DBT (FFDM occult), 100%
were node-negative, in contrast to 87% of FFDM visible cancers, a non-significant
finding.29
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2.5 Conclusion
In consensus with the two European trials, STORM and OTST, all fourteen of the US
studies included in this review appreciated significant reductions in recall rate from DBT
versus FFDM alone, with relative recall rate reductions ranging from 15% to 63%. All
but one of the fourteen studies reported an increase in the overall CDR with DBT versus
FFDM and, although most studies were underpowered to detect significant changes in
cancer detection, five publications reported significant increases in the overall CDR with
the addition of DBT to screening mammography. The single report that observed a slight
increase in overall CDR with FFDM alone versus DBT was far from reaching statistical
significance, and was similarly the only study to observe a non-significant decrease in the
invasive CDR.32 The remaining thirteen US studies observed an increase (n=12) or no
change (n=1) in the invasive CDR with DBT versus FFDM alone, though only four of
these studies were powered to achieve statistical significance. A single study reported an
equal invasive CDR with DBT versus FFDM alone; however, with a total sample size of
only 1,048, this study was significantly underpowered to observe significant changes in
cancer detection, with only one invasive cancer (1/524) detected per modality.33 Both
prospective European trials reported statistically significant increases in the invasive
CDR with DBT versus FFDM alone.9-13 Thirteen of the fourteen US studies reported no
significant difference in the in situ CDR, with most reporting nearly equal or slightly
decreased rates with DBT versus FFDM alone. The same study that reported an equal
invasive CDR found a non-significant increase the in situ CDR with DBT versus FFDM,
again due to the very small sample size resulting in detection of two cases of DCIS with
DBT (2/524) and one case of DCIS with FFDM (1/524).33 None of the reports from the
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two European trials, and only one of the fourteen US studies, observed a significant
increase in the in situ CDR, though the authors offered no explanation of this finding,
which likely represents an outlier.21 Each of the nine studies that evaluated positive
predictive value from recall (PPV1) noted increases with DBT versus FFDM alone, with
seven studies achieving significance. Importantly, two recent studies found that the
benefits of DBT screening are sustainable over subsequent screening rounds.27,28
Several studies noted preferential benefits from screening with DBT in certain
subgroups – in particular, women with no prior mammograms available for comparison
(baseline exams) – though it seems most likely that all women derive benefits from
screening with DBT. Taken together, the evidence from the European screening trials,
STORM and OTST, in addition to the US screening studies, strongly suggest that DBT,
as compared to FFDM alone, significantly reduces recall rate and false positive recalls,
with no significant change in the false negative recall rate; significantly increases CDR
(overall and invasive) with no change the in situ CDR; and yields a higher PPV1.
Finally, there is a dearth of evidence in the literature characterizing screen-detected
cancer. Evidence to date suggests that DBT may have a role in detecting invasive, lowgrade, node-negative cancers, but this is far from established. A detailed analysis of the
characteristics of DBT-detected versus FFDM-detected cancers is warranted, and our
proposed study aims to address this crucial gap in knowledge.
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CHAPTER III: STUDY METHODS
3.1 Study Design
We will conduct a retrospective observational case-control study evaluating screening
outcomes and tumor characteristics in women screened with DBT versus FFDM alone.
The statistician(s) will be blinded to imaging modality during analyses.
3.2 Study Population and Sampling
We utilized convenience sampling from our existing electronic breast imaging
database (PenRad; PenRad Technologies, Buffalo, MN) for all women presenting for
screening mammography at a large academic center. From August 1, 2008 to August 1,
2016, a total of 44,050 women were screened with either full-field digital mammography
(FFDM) alone or digital breast tomosynthesis (DBT) plus FFDM. From August 1, 2008
through July 31, 2011, all women presenting for screening underwent FFDM. In August
2011, our facility switched to DBT for screening. This was offered at no cost to all
women, with the exception of those with implants and very large breasts so as not to
exceed radiation dose standards. Women presenting for breast cancer screening from
August 1, 2008 to July 31, 2011 (years 1-3; n=15,768) were screened with two-view
craniocaudal (CC) and mediolateral (MLO) oblique FFDM alone. Women presenting for
breast cancer screening from August 1, 2011 to August 1, 2016 (years 4-8; n=28,282)
were imaged with combined DBT and FFDM per the current FDA-approved protocol,
again consisting of standard CC and MLO of each breast.
The total number of women recalled from screening (total BI-RADS 0 cases) and
recall rate (RR) have already been measured and reported, and will be discussed below.
To detect the positive predictive value from recall (PPV1) and the CDR, the population of
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interest for this study includes the number of women recalled from screening (BI-RADS
0 cases) with DBT (years 4-8; n=2,194) versus FFDM alone (years 1-3; n=1,761).
3.2.1 Inclusion Criteria
For both cohorts, screening is defined as asymptomatic women (no clinical signs
and/or symptoms of breast cancer). Thus, all asymptomatic women presenting for
screening mammography are included in the total number screened. This also includes
some women with a prior history of cancer and/or breast surgery.
3.2.2 Exclusion Criteria
Women screened with FFDM alone after the FFDM-to-DBT transition period have
been excluded from analyses. As noted, women with very large breasts and/or implants
were not offered screening with DBT so as not exceed radiation dose standards, and have
been excluded from analyses. Diagnostic FFDM or DBT exams have also been excluded.
3.3 Subject Protection and Confidentiality
This will be an Institutional Review Board (IRB)-approved, Health Insurance
Portability and Accountability Act (HIPAA)-compliant retrospective observational study
evaluating data from screening examinations performed between July 2008 and August
2016. We have submitted a request for waiver of obtained written consent to the IRB
(Appendix D). No identifying personal health information will be shared, as we are
assessing data at a population level. All data will be kept on a private, password
protected, encrypted server at YNHH.
3.4 Screening Interpretation and Data Collection
Screening mammograms were acquired with Hologic DimensionsTM units. The
imaging protocol for FFDM consisted of acquiring 2D images in the standard projections
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for both breasts. The imaging protocol for DBT consisted of acquiring 2D images along
with tomosynthesis images (dual acquisition DBT/FFDM) in the standard projections for
both breasts. Thus, bilateral CC and MLO images were obtained for each exam. All
screening mammograms were interpreted prospectively by the same group of eleven
dedicated breast radiologists, the majority of whom are fellowship trained, with a median
of fifteen years of breast imaging experience (range: 5-30 years). All radiologists were
formally trained and certified in DBT interpretation.
The PenRad electronic breast-imaging database will be queried to quantify the total
number of women screened throughout the study period from August 1, 2008 to July 31,
2011 (FFDM-only group) and August 1, 2011 to August 1, 2016 (DBT group).
Population demographics for all women screened (age at screening, breast density,
race/ethnicity, and presence of prior mammography) will be obtained from the PenRad
database and EPIC, the electronic medical record system at Yale New-Haven Hospital
(YNHH). The PenRad database will be used to extract all BI-RADS 0 cases.
For secondary analyses, the PenRad database will be specifically queried for true
positive BI-RADS 0 cases over the study period. Cancer detection rate will be calculated
as the number of true positive BI-RADS 0 cases per 1000 women screened. Tumor size
and characteristics will be obtained from pathology reports in EPIC electronic medical
records. Our data will be cross-linked with the Connecticut Tumor Registry to identify
cancer cases that went to another institution, as permitted by our approved IRB protocol.1
3.5 Study Variables and Outcome Measures
We have retrospectively compared and reported the following outcomes from DBT
versus FFDM alone for all asymptomatic women presenting for screening mammography
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during 8 consecutive years: the total number of women screened (total exams); the total
number of women recalled from screening (BI-RADS 0 cases); and the recall rate (RR)
(%), calculated as the number of BI-RADS 0 examinations divided by the total number of
screening examinations (Table 2).1 Differences in the RR from screening with DBT
versus FFDM alone were assessed using comparison of proportions and tested for
significance with the Pearson chi-squared test. A p value of <0.05 was considered to be
statistically significant. The number of true positive (biopsy-proven) BI-RADS 0 cases
will determine the total cancers detected per modality, and the cancer detection rate
(CDR) will be reported as the proportion of true positive BI-RADS 0 cases per 1000
women screened.
Table 2. Proposed Study: Screening Outcomes
FFDM

DBT

p-value

Total Screening Exams, n1
15,768
28,282
-BI-RADS 0 Cases (Total Recalled), n1
1,761
2,194
-Recall Rate (RR) (%)1
11.17
7.76
<0.001
Cancers Detected, n
-CDR per 1000 screened
Invasive, n
-In situ, n
-PPV1 (%)
DBT=Digital Breast Tomosynthesis; FFDM=Full-Field Digital Mammography; CDR=Cancer Detection
Rate; PPV1=Positive Predictive Value from Recall; RR=Recall Rate.

The primary focus of this study will be retrospective comparison of true positive BIRADS 0 cases as detected with DBT versus FFDM alone for the assessment of PPV1 and
CDR, in addition to quantifying tumor size and characteristics.
3.5.1 Independent Variables
The main independent variable in this study is the modality of screening (DBT versus
FFDM alone). Other independent variables, considered to be confounding factors,
include breast composition (BI-RADS assessment of density); age at screening;
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race/ethnicity; and number of prior screening rounds. Confounding factors will be
controlled for by means of multivariate logistic regression analysis.
3.5.2 Dependent Variables
The main dependent variables (primary outcomes of interest) among the two imaging
modalities include the PPV1 and CDR. In true positive BI-RADS 0 cases, the main
dependent variables include pathologic size and stage at diagnosis; histological type and
grade; and axillary lymph node status and receptor phenotype of invasive cancers.
Dependent variables that have already been measured (Table 2) include the total number
of women screened, the total number of women recalled (BI-RADS 0 cases), and the
recall rates (RR, %) for DBT versus FFDM alone.
3.5.3 Primary Outcomes
Our primary outcomes include identifying the number of true positive BI-RADS 0
cases, which will determine the PPV1, per total number of BI-RADS 0 cases, and the
cancer detection rate (CDR), per 1000 women screened.
3.5.4 Secondary Outcomes
Our secondary outcomes focus on the histologic characteristics of the true positive
BI-RADS 0 cases detected with DBT versus FFDM alone, and will be derived from
pathology reports in patient electronic medical records accessed through EPIC. Outcomes
include tumor size in centimeters (cm); pathologic stage at diagnosis (TNM staging; see
Figure 2, Appendix C); histological type (ductal, lobular, or other) and grade (low,
intermediate, or high nuclear grade for in situ cancers; Nottingham histologic grade 1, 2,
or 3 for invasive); axillary lymph node status and receptor phenotype (ER+/PR+ or
luminal; HER2+; triple negative; see Figure 3, Appendix C) of invasive cancers.
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3.6 Calculation of Power
Power was calculated with PS, version 3.1.2 (Appendix E).2
We will evaluate fixed sample sizes of 2,194 BI-RADS 0 cases recalled from DBT
screening and 1,761 BI-RADS 0 cases recalled from FFDM screening. Prior data indicate
that the positive predictive value from recall (PPV1) among BI-RADS 0 patients recalled
from FFDM is 4.4%.3 Assuming a PPV1 of 4.4% (0.044) for the FFDM group and an
alpha of 0.05, if the PPV1 for the DBT group is at least 6.45% (0.0645), we will be able
to reject the null hypothesis that there is no difference in PPV1 for DBT and FFDM alone
with power of 0.805.
Our study is not powered to detect significant differences in cancer detection.
3.7 Analyses
3.7.1 Univariate and Bivariate Analyses
Baseline characteristics of asymptomatic women screened with DBT versus FFDM
alone will be compared by means of the following statistical tests: age at screening
(unpaired t-test if parametric, Mann Whitney U if non-parametric); BI-RADS breast
density (category A, B, C, or D; Pearson chi-squared); race/ethnicity (Pearson chisquared); and presence or absence of prior screening mammogram (Pearson chi-squared).
All tests will be two-sided, with significance of p<0.05.
Primary Outcome: RR, CDR, and PPV1 from DBT versus FFDM alone will be
compared overall using a two-sided Pearson chi-squared test, with significance of p<0.05
(Table 2). These outcomes will additionally be stratified according to breast density, as
defined by the BI-RADS breast composition categories (Table 3) and patient age (Table
4) at screening (<40 years; 40-49 years; 50-59 years; 60-69 years; ≥70 years).
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Table 3. Proposed Study: Screening Outcomes by Breast Density
Breast Density Stratification
Total Exams, n
RR (%)
Cancers, n
CDR per 1000
Invasive, n
In situ, n
PPV1 (%)

BI-RADS A
DM DBT p
-

BI-RADS B
DM
DBT p
-

BI-RADS C
DM
DBT
p
-

BI-RADS D
DM
DBT
p
-

-

-

-

-

-

-

-

-

DM=Digital Mammography, aka Full-Field DM (FFDM); DBT=Digital Breast Tomosynthesis;
CDR=Cancer Detection Rate; PPV1=Positive Predictive Value from Recall.

Table 4. Proposed Study: Screening Outcomes by Age
Age Stratification
<40 years
40-49 years
50-59 years
60-69 years
≥70 years
DM DBT p DM DBT p DM DBT p DM DBT p DM DBT
Total Exams, n
RR (%)
Cancers, n
CDR per 1000
Invasive, n
In situ, n
PPV1 (%)
DM=Digital Mammography, aka Full-Field DM (FFDM); DBT=Digital Breast Tomosynthesis;
CDR=Cancer Detection Rate; PPV1=Positive Predictive Value from Recall.

p

-

Secondary Outcomes: Assuming parametric data, mean differences in tumor size
(cm) with standard deviations will be compared using an unpaired t-test; if nonparametric, we will use the Mann Whitney U test and report tumor size (cm) as medians
with interquartile ranges. The Pearson chi-squared test will be used to compare histologic
types of cancer (ductal, lobular, other); Nottingham histologic grades; receptor
phenotypes, percent of invasive cancers with axillary lymph node involvement; and
pathologic stage at diagnosis. All tests will be two-sided with significance of p<0.05.
3.7.2 Multivariate Analyses
Multivariate logistic regression analysis and calculation of odds ratios (OR) with
associated 95% confidence intervals (CI) will be utilized to determine the significance of
the difference between the RR, CDR, and PPV1 across FFDM and DBT groups after
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controlling for possible confounding factors. A priori, we will adjust the logistic
regression models for BI-RADS breast density category (A, B, C, or D); patient age at
screening (<40; 40-49; 50-59; 60-69; ≥70); race (Caucasian, African American, Asian,
Other/Unknown), ethnicity (Hispanic, non-Hispanic, Other/Unknown); and presence or
absence of prior screening mammogram. We will apply a generalized linear mixed
random-reader model to adjust for individual radiologist performance. For variables with
more than two levels, we will apply the Bonferroni correction method to the calculation
of OR and 95% CI.
In supplementary analyses (Appendix F), we will further adjust for the following
additional known breast cancer risk factors in a random subset of our population: family
history and/or personal history of breast cancer; BRCA mutation; BMI; reproductive
factors; Jewish ancestry; and number of prior screens. We will obtain this information by
assigning randomized, de-identified numbers to our cases and querying our databases.
3.8 Timeline and Resources
Due to the retrospective nature of this study, our data already exist and are accessible
through the aforementioned databases. Personnel for this study will include one attending
physician, one breast imaging fellow, one pathologist, one medical oncologist, and one
physician assistant student for data retrieval, organization, and statistical analyses.
Necessary resources for this study include access to the PenRad database; the
Connecticut Tumor Registry; and EPIC.
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CHAPTER IV: CONCLUSION
4.1 Advantages and Disadvantages
Our study will address a critical evidence gap in screening with DBT versus FFDM
alone by characterizing the biologic characteristics of cancers detected with DBT versus
FFDM alone, with complete follow-up data in women screened during the study period.
We will evaluate screening outcomes and tumor characteristics in a diverse screening
population from a large, urban academic center. The DBT transition period was fairly
swift at our institution, minimizing possible selection bias. The participating eleven
radiologists have been involved throughout the entirety of the study. Our retrospective
study design is useful for studying rare outcomes, such as development of breast cancer,
and several known confounding factors will be evaluated and controlled for.
Furthermore, we will account for any group differences observed across modalities, with
baseline characterization including age, breast density, race/ethnicity, and
presence/absence of prior exams for all subjects. In a random subset of the population, we
will further adjust for additional known breast cancer risk factors (Appendix F) to best
account for underlying systemic population differences. Group differences will be
accounted for in our multivariate regression analyses, enhancing our internal validity;
minimizing potential selection bias; and allowing for evaluation of the direction and
magnitude of confounding factors. Outcomes will be stratified by age, breast density, and
baseline examination status in order to determine which subgroups, if any, derive
preferential benefit from screening with DBT.
The major disadvantage from screening with dual acquisition DBT is the increased
radiation dose, which is nearly doubled with adjunct DBT. While beyond the scope of
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this study, several publications investigating the use of DBT with reconstructed synthetic
2D (s-2D) images, an imaging technique developed to address the burden of increased
radiation dose exposure in women undergoing dual acquisition DBT, have observed noninferior or superior performance metrics in screening with DBT plus s-2D as compared to
the conventional DBT plus FFDM.1-3 Our study is a natural, retrospective, observational
study in a screening population that has converted from FFDM to DBT, with no
randomization of patients to imaging modalities. Selection bias is a possibility and is
difficult to control for, and could distort the exposure-outcome association, though DBT
screening after the transition date has been offered to every woman, with the exception of
women with very large breasts and/or implants so as not to exceed radiation dose
standards. Since our population stems from a single institution, external validity
(generalizability) is difficult to assess. Information bias is unlikely, since subjects are not
self-reporting their outcomes; furthermore, if present, any information bias is likely nondifferential misclassification, with similar bias across all participants, since variables
were measured at the time of screening and before disease detection. Finally, while this
study is not powered to detect significant differences in cancer detection, our outcomes
will provide valuable insight into the characteristics of cancers detected with screening
DBT versus FFDM alone.
4.2 Clinical Significance
This study will assess outcomes and tumor characteristics in women screened with
DBT versus FFDM alone, providing insight into the biology of cancers detected across
these modalities. Our results thus far are already in accordance with all DBT screening
publications to date, with a significant reduction in recall rate.4 To our knowledge, no
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screening study to date has reported complete follow-up data regarding tumor
characteristics detected with DBT versus FFDM alone, including pathologic size, grade,
and stage at diagnosis; histologic type; axillary lymph node status and receptor phenotype
of invasive cancers. If our hypotheses are correct and in agreement with findings
discussed in our review of the literature (Chapter II) – namely, that DBT-detected cancers
are found to be smaller in size,5 primarily invasive and node-negative5,6 – our results will
have profound implications, suggesting that DBT leads to earlier detection of breast
cancer than does FFDM alone, conceivably leading to less systemic treatment and
improved clinical outcomes. Overall, these outcomes would validate evidence that
screening with DBT reduces harms, as evidenced by decreases in recall rates with no
increase in false negative cases. While higher cancer detection rates could raise potential
for over-diagnosis, characterization of cancers as smaller, lower stage, and with primarily
negative axillary lymph node spread suggests there would be a downstream benefit from
DBT screening, theoretically reducing disease morbidity and mortality.
In future studies, it will be important to evaluate and compare the number of
additional mammographic views required for cancer diagnosis for true positive cases
recalled from DBT versus FFDM7, in addition to the radiologic features (mammographic
abnormalities) leading to recall across modalities.8,9 While beyond the limits of the
maximum allotted time period of two years, a large, prospective study would allow for
causal inference, strengthening existing DBT screening data.
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APPENDIX A: United States Studies (Chapter II), Tables
Table 5. US Study Characteristics
Study: Author/Publication Year/Location/Study Period
Sharpe et al., 2016
Prospective with retrospective cohort; Single-site (Boston, MA)
Two time periods: FFDM (retrospective), DBT (prospective)
January 2011 - March 2014
Conant et al., 2016
Retrospective; Multisite (PA, VT, MA)
One time period: FFDM vs. DBT in sites transitioning to DBT
January 2011 - January 2015
McDonald et al., 2016
Retrospective; Single-site (Philadelphia, PA)
Four time periods: FFDM-0 (Reference), DBT-1, DBT-2, DBT-3
September 2010 - October 2014
Lourenco et al., 2015
Retrospective; Single-site (Providence, RI)
Two time periods: FFDM followed by DBT
March 2011 - March 2013
Sumkin et al., 2015
Prospective; Single-site (Pittsburgh, PA)
One time period: FFDM vs. DBT (paired, independent reads)
May 2010 - September 2014
McDonald et al., 2015
Retrospective; Single-site (Philadelphia, PA)
Two time periods: FFDM followed by DBT for two groups
September 2010 - March 2013

Study N (Mean Age)

Radiologists/Reading Method, Views

DBT: 5,703 (55.68 years)
FFDM: 80,149 (57.62 years)

10 radiologists
Average experience: 15.6 years

Total: 85,852
DBT: 55,998 (avg. n/a)
FFDM: 142,883 (avg. n/a)

Single-reading; Two view
47 radiologists
All had interpreted at least 50 DBT and FFDM screening exams

Total: 198,881
DBT-3: 11,576 (56.7 years)
DBT-2: 11,157 (56.9 years)
DBT-1: 11,007 (56.7 years)
FFDM-0: 10,728 (56.9 years)
Total: 44,468
DBT: 12,921 (55.3 years)
FFDM: 12,577 (54.6 years)

Single-reading; Two-view
7 radiologists
Experience range: 8-26 years

Total: 25,498
DBT: 1,074 (42 years)
FFDM: 1,074 (42 years)

Single-reading; Two-view
14 radiologists
Experience range: 5-28 years (FFDM); 3-9 years (DBT)

Total: 1,074
DBT: 15,571 (see subgroups)
FFDM: 10,728 (see subgroups)

Single-reading, independent: Two-view
6 radiologists
Experience range: 3-22 years

Total: 26,299§
Baseline Subgroup:
DBT: 1,895 (48.9 years)
FFDM: 1,204 (49.2 years)
Total: 3,063

Single-reading; Two-view
6 radiologists
Experience range: 4-16 years

Single-reading; Two-view
Previously Screened:
DBT: 13,712 (57.8 years)
FFDM: 9,524 (57.9 years)
Total: 23,236

§Same population as McCarthy et al. (2014)

Table 5 (continues)
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Study: Author/Publication Year/Location/Study Period
McCarthy et al., 2014
Retrospective; Single-site (Philadelphia, PA)
Two time periods: FFDM followed by DBT
September 2010 - March 2013
Greenberg et al., 2014
Retrospective; Multisite: 6 sites total (MD, VA, DC)
One time period: FFDM vs. DBT
August 2011 - December 2012
Friedewald et al., 2014
Retrospective; Multisite (13): 5 academic, 8 non-academic
Two time periods: FFDM followed by DBT
March 2010 - January 2013
Destounis et al., 2014
Retrospective; Single-site (Rochester, NY)
One time period: FFDM (age-matched) vs. DBT
June 2011 - December 2011
Durand et al., 2015
Retrospective; Academic center: 4 sites (New Haven, CT)
One time period: FFDM vs. DBT
August 2011 - January 2013
Haas et al., 2013
Retrospective; Academic center: 4 sites (New Haven, CT)
One time period: FFDM vs. DBT
October 2011 - October 2012
Rose et al., 2014
Prospective w/paired retrospective cohort; Single-site (Houston, TX)
One time period: FFDM (retrospective) vs. DBT (prospective); paired
May 2011 to February 2012
Rose et al., 2013
Retrospective; Single-site (Houston, TX)
Two time periods: FFDM followed by DBT
2010 - February 2012

Study N (Mean Age)

Radiologists/Reading Method, Views

DBT: 15,571 (56.7 years)
FFDM: 10,728 (56.9 years)

6 radiologists
Experience range: 3-22 years

Total: 26,299§
DBT: 20,943 (59.6 years)
FFDM: 38,674 (59.5 years)

§Same population as McDonald et al. (2015)
Single-reading; Two-view
14 radiologists; interpreted >500 DBT images
Experience range: 2-38 years

Total: 59,617
DBT: 173,663 (56.2 years)
FFDM: 281,187 (57 years)

Single-reading; Two-view
139 radiologists at 13 different sites

Total: 454,850
DBT: 524 (59 years)
FFDM: 524 (59 years)

Single-reading; Two-view
Note: all analyses adjust for site as a random effect
6 radiologists
Experience range: 1-35 years

Total: 1,048
DBT: 8,591 (avg. n/a)
FFDM: 9,364 (avg. n/a)

Double-reading; Two-view
7 radiologists
Experience range: 2-25 years

Total: 17,955*
DBT: 6,100 (55.8 years)
FFDM: 7,058 (57.5 years)

Single-reading; Two-view
8 radiologists
Experience range: 2-23 years

Total: 13,158*
DBT: 10,878 (avg. n/a)
FFDM: 10,878 (avg. n/a)
Total: 10,878
DBT: 9,499 (54.5 years)
FFDM: 13,856 (53.8 years)

Single-reading; Two-view
10 radiologists prospectively read DBT+FFDM
7 radiologists retrospectively read corresponding FFDM exams alone
Experience range: 2-32 years
Single-reading; Two-view
6 radiologists; interpreted >500 images before & after DBT transition
Experience range: 2-32 years

Total: 23,355

Single-reading; Two-view

*13,158 subjects reported in Haas et al. 2013

Table 5
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Table 6. Screening Outcomes: US Studies
Study
Sharpe et al., 2016
DBT: 5,703
FFDM: 80,149
Total: 85,852

Conant et al., 2016
DBT: 55,998
FFDM: 142,883
Total: 198,881 exams
from 103,401 women

Recall Rate

Cancers Detected

DBT: 6.1%
FFDM: 7.51%
Relative reduction: 18.8%
*p<0.0001
Unadjusted OR: 0.80 (0.72-0.90)
*p<0.0001
Adjusted OR: 0.98 (0.84-1.13)
p=0.7458 N.S.
DBT: 8.7%
FFDM: 10.4%
Relative reduction: 16.3%
*p<0.0001
Adjusted OR: 0.68 (0.65-0.71)

DBT: 31
Invasive: 16 (51.5%)
DCIS: 15 (48.5%)
FFDM: 280
Invasive: 197 (70.4%)
DCIS: 83 (29.6%)

CDR per 1000

Invasive CDR/1000

DBT: 5.4
FFDM: 3.5
Relative increase: 54.3%

DBT: 2.81
FFDM: 2.46
Relative increase: 12.6%

*p<0.0018

p=0.61 N.S.

DBT: 149
DBT: 5.9
Invasive: 106 (71.1%) FFDM: 4.4
DCIS: 43 (28.9%)
Relative increase: 34.1%
FFDM: 499
*p=0.0026
Invasive: 378 (75.8%) Adjusted OR: 1.45 (1.12-1.88)
DCIS: 121 (24.2%)

DBT: 4.2
DBT: 0.77
FFDM: 3.3
FFDM: 0.85
Relative increase: 27.3%
*p=0.045
N.S.
Adjusted OR: 1.38 (1.02-1.87)

False Negative Rate per 1000:
DBT: 0.60
FFDM: 0.46
p=0.347 N.S.
McDonald et al., 2016
DBT-3: 11,576
DBT-2: 11,157
DBT-1: 11,007
FFDM-0: 10,728
Total: 44,468 exams
from 23,958 women
Sumkin et al., 2015
DBT: 1,074
FFDM: 1,074
Total: 1,074 (paired)
Lourenco et al., 2015
DBT: 12,921
FFDM: 12,577
Total: 25,498

DBT-3: 9.2%
OR: 0.87 (0.80-0.95) *p=0.002
DBT-2: 9.0%
OR: 0.85 (0.78-0.93) *p<0.001
DBT-1: 8.8%
OR: 0.83 (0.76-0.91) *p<0.001
FFDM-0 (Ref): 10.4%
N.S. across DBT years (p=0.55)
DBT: 25.5%
FFDM: 38.4%
Relative reduction: 33.6%
*p<0.001
DBT: 6.4%
FFDM: 9.3%
Relative reduction: 31.2%
*p<0.00001

DCIS CDR/1000
DBT: 2.63
FFDM: 1.04
Relative increase:
153%
*p<0.0006

Sensitivity:
DBT: 90.9%
FFDM: 90.6%
p=1.00 N.S.
n/a

DBT-3: 6.1
OR: 1.35 (0.93-1.94); p=0.11
DBT-2: 5.8
OR: 1.28 (0.88-1.85); p=0.20
DBT-1: 5.5
OR: 1.35 (0.93-1.94); p=0.37
FFDM-0 (Ref): 4.6
N.S. vs. FFDM or across DBT
n/a

DBT-3: 4.1
DBT-2: 4.1
DBT-1: 3.8
FFDM-0 (Ref): 3.2

DBT-3: 1.8
DBT-2: 1.3
DBT-1: 1.5
FFDM-0 (Ref): 1.4

N.S. vs. FFDM or across DBT
n/a

N.S. vs. FFDM or
across DBT years
n/a

PPV1
n/a

DBT: 6.4%
FFDM: 4.1%
Relative increase: 56.1%
*p<0.0001
Adjusted OR: 2.02 (1.54-2.65)
Specificity:
DBT: 91.3%
FFDM: 89.7%
*p<0.0001
Adjusted OR: 1.39 (1.30-1.48)
DBT-3: 6.7%
OR: 1.56 (1.07-2.26); *p=0.02
DBT-2: 6.5%
OR: 1.51 (1.03-2.21); *p=0.03
DBT-1: 6.2%
OR: 1.44 (0.98-2.12); p=0.06 N.S.
FFDM-0 (Ref): 4.4%
N.S. across DBT years
n/a

6 total
DBT only: 1
FFDM only: 1
Both: 4
DBT: 60
DBT: 4.6
DBT: 2.32
DBT: 1.63
DBT: 6.2%
Invasive: 30 (50%)
FFDM: 5.4
FFDM: 3.26
FFDM: 1.67
FFDM: 5.2%
DCIS: 21 (35%)
Relative decrease: 14.8%
Relative decrease: 28.8%
Relative increase: 19.2%
FFDM: 68
p=0.44 N.S.
N.S.
N.S.
p=0.219 N.S.
Invasive: 41 (60.3%)
Specificity:
DCIS: 21 (30.9%)
DBT: 94% | FFDM: 91.1% N.S.
Unadjusted/Adjusted ORs: #s in parentheses denote 95% CI intervals. Acronyms/Abbreviations: Breast Imaging-Reporting and Data System (BI-RADS); Cancer Detection Rate (CDR); Confidence Interval
(CI); Ductal Carcinoma in situ (DCIS); Digital Breast Tomosynthesis (DBT); Full-Field Digital Mammography (FFDM); Odds Ratio (OR); Positive Predictive Value (PPV1) from Recall; Reference (Ref)
* = Significant; N.S. = Not significant
Table 6 (continues)
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Study
McDonald et al., 2015
Baseline subgroup:
DBT: 1,895
FFDM: 1,204
Total: 3,063

Previously screened:
DBT: 13,712
FFDM: 9,524
Total: 23,236
Overall:
DBT: 15,571
FFDM: 10,728
Total: 26,299
McCarthy et al., 2014
DBT: 15,571
FFDM: 10,728
Total: 26,299

Destounis et al., 2014
DBT: 524
FFDM: 524
Total: 1,048

Recall Rate
Baseline subgroup:
DBT: 16.0%
FFDM: 20.5%
Relative reduction: 22%
*p=0.002
Adjusted OR: 0.74 (0.61-0.89)
*p=0.002
Previously screened:
DBT: 7.8%
FFDM: 9.1%
Relative reduction: 14.3%
*p<0.001
Adjusted OR: 0.84 (0.76-0.92)
*p<0.001

Cancers Detected
Baseline subgroup:
DBT: 11
FFDM: 5

Previously screened:
DBT: 74
FFDM: 44

DBT: 8.8%
DBT: 85
FFDM: 10.4%
Invasive: 60 (71%)
Relative reduction: 15.4%
DCIS: 23 (27%)
*p<0.001
FFDM: 49
Unadjusted OR: 0.82 (0.75-0.89) Invasive: 34 (69%)
*p<0.001
DCIS: 15 (32%)
Adjusted OR: 0.80 (0.74-0.88)
*p<0.001
DBT: 4.20%
FFDM: 11.45%
Relative reduction: 63.3%
*p<0.0001

CDR per 1000
Baseline subgroup:
DBT: 5.9
FFDM: 4.2
Relative increase: 40.5%
p=0.51 N.S.

Invasive CDR/1000
n/a

DCIS CDR/1000
n/a

Previously screened:
DBT: 5.4
FFDM: 4.6
Relative increase: 17.4%
p=0.41 N.S.

n/a

n/a

DBT: 5.5
FFDM: 4.6
Relative increase: 19.6%
p=0.32 N.S.
Under age 50:
DBT: 5.7
FFDM: 2.2
Relative increase: 159%
*p=0.02
DBT: 5.7
FFDM: 3.8
Relative increase: 50%
p=0.15 N.S.

DBT: 3.9
FFDM: 3.2
Relative increase: 21.9%
p=0.36 N.S.

DBT: 1.5
FFDM: 1.4
p=0.87 N.S.

PPV1
Baseline subgroup:
DBT: 3.7%
FFDM: 2.0%
p=0.25 N.S.
Adjusted OR: 1.81 (0.61-5.43)
p=0.29 N.S.
Previously screened:
DBT: 6.9%
FFDM: 5.1%
Relative increase: 35.3%
p=0.09 Trending, N.S.
Adjusted OR: 1.57 (1.05-2.33)
*p=0.03

DBT: 6.2%
FFDM: 4.4%
Relative increase: 41%
*p=0.047
Under age 50:
DBT: 7.4%
FFDM: 6.3%
Relative increase: 17.5%
*p=0.007
DBT: 13.6%
FFDM: 3.33%
Relative increase: 308%
N.S.

DBT: 3
DBT: 1.90
DBT: 3.82
Invasive: 1 (33%)
FFDM: 1.90
FFDM: 1.90
DCIS: 2 (67%)
Relative increase: 0%
FFDM: 2
N.S.
N.S.
Invasive: 1 (50%)
DCIS: 1 (50%)
Greenberg et al., 2014 DBT: 13.6%
DBT: 144
DBT: 6.3
DBT: 4.6
DBT: 1.6
DBT: 4.6%
DBT: 20,943
FFDM: 16.2%
Invasive: 106 (73.6%) FFDM: 4.9
FFDM: 3.2
FFDM: 1.7
FFDM: 3.0%
FFDM: 38,674
Relative reduction: 16%
DCIS: 37 (25.7%)
Relative increase: 28.6%
Relative increase: 43.8%
Relative increase: 53.3%
Total: 59,617
*p<0.0001
Other: 1 (0.7%)
*p=0.035
*p=0.006
p=0.753 N.S.
*p=0.0003
Generalized Linear Mixed
FFDM: 203
GLMM: 27.11% increase
GLMM: 51.14% increase
Model (GLMM): 13.60%
Invasive: 126 (62.1%) *p=0.0409
*p=0.0007
reduction
DCIS: 75 (36.9%)
*p<0.0001
Other: 2 (1.0%)
Unadjusted/Adjusted ORs: #s in parentheses denote 95% CI intervals. Acronyms/Abbreviations: Breast Imaging-Reporting and Data System (BI-RADS); Cancer Detection Rate (CDR); Confidence Interval
(CI); Ductal Carcinoma in situ (DCIS); Digital Breast Tomosynthesis (DBT); Full-Field Digital Mammography (FFDM); Odds Ratio (OR); Positive Predictive Value (PPV1) from Recall; Reference (Ref)
* = Significant; N.S. = Not significant
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Study
Friedewald et al., 2014
DBT: 173,663
FFDM: 281,187
Total: 454,850

Recall Rate
DBT: 9.1%
FFDM: 10.7%
Relative reduction: 15%
*p<0.001

Durand et al., 2015
DBT: 8,591
FFDM: 9,364
Total: 17,955£

DBT: 7.8%
FFDM: 12.3%
Relative reduction: 36.6%
*p<0.0001
Adjusted OR: 1.76 (1.58-1.96)
£
13,158 from Haas 2013 *p<0.0001 (1.76x higher FFDM)
Haas et al., 2013
DBT: 8.4%
DBT: 6,100
FFDM: 12%
FFDM: 7,058
Relative reduction: 30%
Total: 13,158£
*p<0.01
Adjusted OR: 0.62 (0.55-0.70)
*p<0.0001
Rose et al., 2014
DBT: 10,878
FFDM: 10,878
Total: 10,878

DBT: 5.41%
FFDM: 8.16%
Relative reduction: 33.7%
*p<0.0001

Rose et al., 2013
DBT: 9,499
FFDM: 13,856
Total: 23,355

DBT: 5.5%
FFDM: 8.7%
Relative reduction: 36.7%
*p<0.001

Cancers Detected

CDR per 1000

DBT: 950
Invasive: 707 (74.4%)
DCIS: 243 (25.6%)
FFDM: 1207
Invasive: 815 (67.5%)
DCIS: 392 (32.5%)

DBT: 5.4
FFDM: 4.2
Relative increase: 28.6%
*p<0.001

DBT: 51
Invasive: 35 (68.6%)
DCIS: 16 (31.4%)
FFDM: 54
Invasive: 35 (64.8%)
DCIS: 19 (35.2%)
DBT: 35
Invasive: 24 (69%)
DCIS: 11 (31%)
FFDM: 37
Invasive: 25 (68%)
DCIS: 12 (32%)
DBT: 59
Invasive: 48 (83.4%)
DCIS: 11 (18.6%)
FFDM: 39
Invasive: 29 (74.4%)
DCIS: 10 (25.6%)

Invasive CDR/1000

DCIS CDR/1000
DBT: 1.4
FFDM: 1.4

DBT: 5.9
FFDM: 5.7
Relative increase: 3.5%
p=0.88 N.S.

DBT: 4.1
FFDM: 2.9
Relative increase: 41.4%
*p<0.001
Invasive Ductal:
DBT: 3.27 FFDM: 2.46
Relative increase: 33%
*p<0.001
Invasive Lobular:
DBT: 0.55 FFDM: 0.27
Relative increase: 103.7%
*p<0.001
DBT: 4.07
FFDM: 3.74
Relative increase: 8.8%
p=0.26 N.S.

DBT: 5.7
FFDM: 5.2
Relative increase: 9.6%
p=0.70 N.S.

DBT: 3.9
FFDM: 3.5
Relative increase: 11.4%
p=0.93 N.S.

DBT: 1.8
FFDM: 1.7

DBT: 5.4
FFDM: 3.5
Relative increase: 54.3%
*p<0.0001

DBT: 4.4
FFDM: 2.7
Relative increase: 63%
*p<0.0001

DBT: 0.92
FFDM: 1.02

p=0.95 N.S.

DBT: 1.9
FFDM: 2.0

PPV1
DBT: 6.4%
FFDM: 4.3%
Relative increase: 48.8%
*p<0.001

n/a

p=0.63 N.S.

n/a

N.S.

n/a

N.S.

DBT: 51
DBT: 5.37
DBT: 4.32
DBT: 1.05
DBT: 10.1%
Invasive: 41 (80.4%)
FFDM: 4.04
FFDM: 2.81
FFDM: 1.22
FFDM: 4.7%
DCIS: 10 (19.6%)
Relative increase: 32.9%
Relative increase: 53.7%
Relative increase: 115%
FFDM: 56
p=0.18 N.S.
p=0.07 Trending, N.S.
N.S.
*p<0.001
Invasive: 39 (69.6%)
DCIS: 17 (30.4%)
Unadjusted/Adjusted ORs: #s in parentheses denote 95% CI intervals. Acronyms/Abbreviations: Breast Imaging-Reporting and Data System (BI-RADS); Cancer Detection Rate (CDR); Confidence Interval
(CI); Ductal Carcinoma in situ (DCIS); Digital Breast Tomosynthesis (DBT); Full-Field Digital Mammography (FFDM); Odds Ratio (OR); Positive Predictive Value (PPV1) from Recall; Reference (Ref)
* = Significant; N.S. = Not significant
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APPENDIX B: Tumor Characteristics (Chapter II), Tables
Table 7. Tumor Characteristics: European Studies
Study
STORM
DBT: 7,294
FFDM: 7,294
Total: 7,294
(paired)

Cancers Detected

Double-Read:
DBT total: 59
Invasive: 52 (88%)
DCIS: 7 (12%)
FFDM & DBT: 39
Invasive: 35 (90%)
DCIS: 4 (10%)
Single-Read:
DBT total: 55
FFDM & DBT: 35
CDR/1000:
DBT: 7.5
Tumor data
FFDM: 4.8
is from
 56.25%
doubleIncremental CDR: 2.7
reading.
*p<0.001
OTST
121 cancers
Single-Read
14 missed by both
DBT: 12,621 DBT only: 30
FFDM: 12,621 FFDM only: 6
Total: 12, 621 DBT+FFDM: 71
(paired)

CDR/1000
Overall
Double-Read:
DBT: 8.1
FFDM: 5.3
 52.8%
*p<0.0001
Incremental
CDR: 2.7
*p<0.0001

Invasive
Double-Read:
DBT: 7.1
FFDM: 4.8
 47.9%
*p<0.0001

In situ
Double-Read:
DBT: 0.96
FFDM: 0.55
N.S.

TNM/Tumor Size
(cm)
Invasive only:
DBT (FFDM occult):
T1a: 0
T1b: 8 (40%)
T1c: 8 (40%)
T2: 1 (5%)
Mean: 1.35
SD: 0.67%
FFDM & DBT:
T1a: 3 (8%)
T1b: 10 (26%)
T1c: 20 (51%)
T2: 2 (5%)
Mean: 1.37
SD: 0.58
(TNM classification)
Invasive only:
DBT Total:
Mean: 1.32
Median: 1.3
Range: 0.1-5.0

Invasive Cancer
Types
IDC: 37 (71%)
ILC: 4 (7.7%)
Other: 7 (14.5%)
Mixed: 4 (7.7%)

# detected with:
FFDM alone: 0
FFDM & DBT: 29
FFDM+DBT: 13
(FFDM occult)

Lymph Node Status

Cancer Grade

Receptor
Phenotype

Invasive only:
DBT (FFDM occult):
DBT Total:
DBT (FFDM occult):
Negative: 11 (55%)
Grade 1: 6 (35%)
ER+/PR+: 11 (92%)
Positive: 3 (15%)
Grade 1-2: 1 (6%) HER2+: 1 (8%)
Micromets or isolated
Grade 2: 7 (41%)
Triple Neg: 0
tumor cells: 1 (5%)
Grade 3: 2 (12%)
No surgery, n/a: 5 (25%) n/a: 1 (6%)
FFDM & DBT:
FFDM & DBT:
Negative: 24 (62%)
Grade 1: 10 (29%)
Positive: 9 (23%)
Grade 1-2: 2 (6%)
Micromets or isolated
Grade 2: 16 (46%)
tumor cells: 2 (5%)
Grade 3: 6 (17%)
No surgery, n/a: 4 (10%) n/a: 1 (3%)

FFDM & DBT:
ER+/PR+: 25 (81%)
HER2+: 4 (13%)
Triple Neg: 2 (6%)

Invasive:
→ DCIS Grade:
DBT Total: 81
DBT Total: 20
Grade 1: 32 (39.5%) Low/Med: 4 (20%)
Grade 2: 35 (43.2%) High: 16 (80%)
Grade 3: 13 (16%)
N.S.
n/a: 1 (1.2%)
FFDM Total: 21
DBT only:
DBT only: 29
DBT only: 29
DBT only: 29
Low/Med: 4 (19%)
ReaderReaderDCIS Size:
DBT Total: 101
Mean: 1.28
IDC: 16 (55%)
Negative: 23 (79.3%)
Grade 1: 14 (48%) High: 17 (81%)
adjusted
adjusted
DBT Total:
DBT Total: all
Invasive: 81 (80%) FFDM:DBT
Median: 1.3
ILC: 7 (25%)
Positive: 4 (13.8%)
Grade 2: 11 (39%)
FFDM:DBT
Mean: 2.53
cases detected DCIS: 20 (20%)
Range: 0.5-5.0
IDC+DCIS: 5 (17%)
n/a: 2 (6.9%)
Grade 3: 3 (10%)
ratio:
ratio:
Median: 1.85
w/DBT+FFDM FFDM Total: 77
Other: 1 (3%)
(FFDM occult)
n/a: 1 (3%)
1.27 (27%)
1.40 (40%) Range: 0.5-8.5 (FFDM occult)
& DBT alone;
Invasive: 56 (72%) (1.06-1.53)
(FFDM occult)
(FFDM occult)
(1.13-1.71)
(FFDM occult)
FFDM Total:
DCIS: 21 (28%)
FFDM Total:
FFDM Total: 56
FFDM Total: 56
FFDM Total: 56
FFDM Total:
all cases
Difference: 24
Mean: 1.32
IDC: 35 (62.5%)
Negative: 44 (78.6%)
Grade 1: 17 (30.4%)
Mean: 2.10
detected w/
Median: 1.1
ILC: 8 (14.3%)
Positive: 9 (16%)
Grade 2: 29 (51.8%)
Median:
1.5
DBT+ FFDM &
Range: 0.1-2.7
IDC+DCIS: 11 (20%) n/a: 3 (5.4%)
Grade 3: 9 (16%)
Range: 0.5-5.0
FFDM alone.
Other: 2 (3.6%)
n/a: 1 (1.8%)
TNM Classification: See Figure 2 | Receptor Phenotypes: See Figure 3 |Acronyms/Abbreviations: Cancer Detection Rate (CDR); Ductal Carcinoma In Situ (DCIS); Digital Breast Tomosynthesis (DBT);
Centimeters (cm); Full-Field Digital Mammography (FFDM); Medium (Med); Invasive Ductal Carcinoma (IDC); Invasive Lobular Carcinoma (ILC); Not available (n/a); Standard Deviation (SD * =
* = Significant; N.S. = Not significant
Table 7
Overall
DBT: 8.0
FFDM: 6.1
31.1%
*p=0.001

Invasive
DBT: 6.4
FFDM: 4.4
45.5%
*p<0.001

In situ
DBT: 1.58
FFDM: 1.66
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DBT Total: 81
DBT Total: 81
IDC: 49 (60.5%)
Negative: 63 (77.8%)
ILC: 13 (16%)
Positive: 13 (16%)
IDC+DCIS: 16 (20%) n/a: 5 (6.2%)
Other: 3 (3.7%)

Table 8. Tumor Characteristics: US Studies
Study
Wang et al.,
2016
FFDM + DBT:
12,444
FFDM → DBT
Total: 12,444
(paired)

Cancers Detected
DBT total: 65
Invasive: 41 (63.1%)
DCIS: 24 (36.9%)
FFDM visible: 55
Invasive: 32 (58.2%)
DCIS: 23 (41.8%)

10 of 65 cases detected
were FFDM occult (seen
only with DBT); 9 of 10
FFDM occult cancers
were invasive (90%)
Greenberg et al., DBT: 144
2014
Invasive: 106 (73.6%)
DBT: 20,943
DCIS: 37 (25.7%)
FFDM: 38,674
Other: 1 (0.7%)
Total: 59,617
FFDM: 203
Invasive: 126 (62.1%)
DCIS: 75 (36.9%)
Other: 2 (1.0%)

Overall
DBT: 5.2
FFDM: 4.4
18.6%

N.S.
Overall
DBT: 6.3
FFDM: 4.9
28.6%
*p=0.035

CDR/1000
Invasive
DBT: 3.3
FFDM: 2.6
26.9%

N.S.
Invasive
DBT: 4.6
FFDM: 3.2
43.8
*p=0.006

In situ
DBT: 1.93
FFDM: 1.85
23/24 DCIS
cases (96%)
found with
FFDM alone

p=0.08
Trending,
N.S.
In situ
DBT: 1.6
FFDM: 1.7

Tumor Size (cm)
Invasive only:
DBT (FFDM
occult): 10
Mean: 0.78
Median: 0.6
Range: 0.3-1.3
FFDM visible: 32
Mean: 1.23
Median: 1.0
Range: 0.4-4.3
p=0.07
Trending, N.S.
n/a

p=0.753
N.S.

Invasive Cancer Types
DBT (FFDM occult): 9
IDC: 6 (60%)
ILC: 1 (10%)
Tubular: 2 (20%)

LN Status (TNM) Invasive Cancer Grade
DBT only: 9
DBT (FFDM occult): 9
N0: 9 (100%)
Grade 1: 7 (78%)
≥N1: 0
Grade 2: 0
Grade 3: 2 (22%)

FFDM visible: 32
IDC: 21 (65.6%)
ILC: 4 (12.5%)
ILC+IDC: 6 (18.8%)
Other: 1 (3.1%)
N.S.
DBT: 106
IDC: 82 (77.4%)
ILC: 18 (17%)
Other: 6 (5.7%)

FFDM visible: 32
N0: 28 (87.5%)
≥N1: 4 (12.5%)

FFDM visible: 32
Grade 1: 15 (47%)
Grade 2+3: 17 (53%)

p=0.6 N.S.
n/a

*p=0.02
DBT: 106
T1mic: 2 (1.9%)
Grade 1: 24 (22.6%)
Grade 2: 61 (57.5%)
Grade 3: 19 (17.9%)
FFDM: 203
T1mic: 4 (3.2%)
Grade 1: 20 (15.9%)
Grade 2: 78 (61.9%)
Grade 3: 22 (17.5%)
Unknown: 2 (1.6%)
p=0.607 N.S.
n/a

FFDM: 126
IDC: 107 (84.9%)
ILC: 16 (12.7%)
Other: 3 (2.4%)

DCIS Grade
n/a

DBT: 37
Low: 5 (13.5%)
Interm: 20 (54%)
High: 12 (32.4%)
FFDM: 75
Low: 3 (4%)
Interm: 32 (43%)
High: 40 (53.3%)

p=0.255 N.S.
*p=0.045
Invasive
In situ
n/a
DBT: 707
n/a
n/a
IDC: 568 (80.3%)
DBT: 4.1
DBT: 1.40
ILC: 95 (13.4%)
FFDM: 2.9
FFDM: 1.39
ILC+IDC: 29 (4.1%)
41.4%
Other: 5 (0.7%)
*p<0.001
N.S.
Unspec.: 10 (1.4%)
IDC:
FFDM: 815
DBT: 3.27
IDC: 693 (85%)
FFDM: 2.46
ILC: 75 (9.2%)
*p<0.001
ILC+IDC: 39 (4.8%)
ILC:
Other: 5 (0.6%)
DBT: 0.55
Unspec.: 3 (0.4%)
FFDM: 0.27
*p<0.001
TNM Classification: See Figure 2 | Acronyms/Abbreviations: Cancer Detection Rate (CDR); Ductal Carcinoma In Situ (DCIS); Digital Breast Tomosynthesis (DBT); Centimeters (cm); Full-Field Digital
Mammography (FFDM); Intermediate (Interm); Invasive Ductal Carcinoma (IDC); Invasive Lobular Carcinoma (ILC); Lymph Node (LN); Not available (n/a); Unspecified (Unspec.)
* = Significant; N.S. = Not significant
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Friedewald et al.,
2014
DBT: 173,663
FFDM: 281,187
Total: 454,850

DBT: 950
Invasive: 707 (74.4%)
DCIS: 243 (25.6%)
FFDM: 1207
Invasive: 815 (67.5%)
DCIS: 392 (32.5%)

Overall
DBT: 5.4
FFDM: 4.2
28.6%
*p<0.001
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Study
Durand et al.,
2015
DBT: 8,591
FFDM: 9,364
Total: 17,955

Cancers Detected
DBT: 51
Invasive: 35 (68.6%)
DCIS: 16 (31.4%)
FFDM: 54
Invasive: 35 (64.8%)
DCIS: 19 (35.2%)

Rose et al., 2013
DBT: 9,499
FFDM: 13,856
Total: 23,355

DBT: 51
Invasive: 41 (80.4%)
DCIS: 10 (19.6%)
FFDM: 56
Invasive: 39 (69.6%)
DCIS: 17 (30.4%)

Overall

CDR/1000
Invasive

DBT: 5.9
FFDM: 5.7
p=0.88

DBT: 4.07
FFDM: 3.74
p=0.26

DBT: 1.9
FFDM: 2.0
p=0.63

N.S.
Overall
DBT: 5.37
FFDM: 4.04
33%
p=0.18

N.S.
Invasive
DBT: 4.32
FFDM: 2.81
53.7%
p=0.07

N.S.
In situ
DBT: 1.05
FFDM: 1.22

In situ

Tumor Size (cm)
Invasive Cancer Types
Invasive only:
n/a
DBT: data for 24
TX: 0
T1: 18 (75%)
T2: 6 (25%)
FFDM: data for 32
TX: 1 (3.1%)
T1: 23 (71.9%)
T2: 8 (25%)
(TNM classification)
N.S.
Invasive only:
DBT:
Mean: 1.6
Median: 1.3
FFDM:
Mean: 1.6
Median: 1.3

DBT: 41
IDC: 34 (83%)
ILC: 6 (14.6%)
ILC+IDC: 1 (2.4%)
Mucinous: 0
FFDM: 39
IDC: 31 (79.4%)
ILC: 3 (7.8%)
ILC+IDC: 4 (10.3%)
Mucinous: 1 (2.5%)
p = 0.69 N.S.

LN Status (TNM)
DBT: 35
n/a: 1 (2.9%)
NX: 2 (5.7%)
N0: 24 (68.6%)
N1: 8 (22.9%)
FFDM: 35
n/a: 3 (8.6%)
NX: 2 (5.7%)
N0: 25 (71.4%)
N1: 4 (11.4%)
N2: 1 (2.9%)
p = 0.84 N.S.

Invasive Cancer Grade
n/a

DCIS Grade
n/a

DBT: 41
Nx: 1 (2.4%)
N0: 34 (83%)
N1: 6 (14.6%)
N2: 0
FFDM: 39
Nx: 2 (5%)
N0: 33 (85%)
N1: 2 (5%)
N2: 2 (5%)
p = 0.84 N.S.

DBT: 41
Grade 1: 16 (39%)
Grade 2: 17 (41%)
Grade 3: 9 (22%)
Unknown: 0
FFDM: 39
Grade 1: 12 (31%)
Grade 2: 11 (28%)
Grade 3: 15 (38.5%)
Unknown: 1 (2.5%)
N.S.

DBT: 10
Low: 0
Interm: 3 (30%)
High: 7 (70%)
FFDM: 17
Low: 3 (17.6%)
Interm: 6 (35%)
High: 7 (41.2%)
Unknown: 1 (6%)

p=0.91
N.S.
N.S.
N.S.
Trending, N.S N.S.
TNM Classification: See Figure __ | Acronyms/Abbreviations: Cancer Detection Rate (CDR); Ductal Carcinoma in situ (DCIS); Digital Breast Tomosynthesis (DBT); Centimeters (cm); Full-Field Digital
Mammography (FFDM); Intermediate (Interm); Invasive Ductal Carcinoma (IDC); Invasive Lobular Carcinoma (ILC); Lymph Node (LN); Not available (n/a); Unspecified (Unspec.)
* = Significant | N.S. = Not significant
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APPENDIX C: Breast Cancer TNM Staging and Receptor Phenotypes
TNM Staging System for Breast Cancer
T: Primary Tumor
TX
T0
Tis
T1
T1mic
T1a
T1b
T1c
T2
T3
T4

Primary tumor cannot be assessed
No evidence of primary tumor
Carcinoma in situ
Tumor ≤ 2.0 cm in greatest dimension
Tumor ≤ 0.1 cm in greatest dimension
Tumor > 0.1 cm but ≤ 0.5 cm in greatest dimension
Tumor > 0.5 cm but ≤ 1 cm in greatest dimension
Tumor > 1.0 cm but ≤ 2.0 cm in greatest dimension
Tumor > 2.0 cm but ≤ 5 cm in greatest dimension
Tumor > 5.0 cm in greatest dimension
Tumor of any size with direct extension into (a) chest wall or (b) skin of breast

N: Regional Lymph Nodes
NX
N0
N1
N2
N3

Regional lymph nodes cannot be assessed
No regional lymph node metastasis histologically, no additional exam for isolated tumor cells
Metastasis in movable ipsilateral axillary lymph node(s)
Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident
axillary lymph node metastasis
Metastasis in ipsilateral infraclavicular lymph node(s), or in clinically apparent ipsilateral internal mammary nodes in the presence of clinically evident axillary
lymph node metastasis; or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement

M: Distant Metastasis
MX
M0
M1

Distant metastasis cannot be assessed
No distant metastasis
Distant metastasis

Figure 2. TNM Staging System for Breast Cancer
Estrogen Receptor (ER)
A
Luminal
B
HER2-Enriched
Triple Negative

Progesterone Receptor (PR)

ER (+) and/or PR (+)
ER (+) and/or PR (+)
(-)
(-)

HER2
(-)
(+)
(+)
(-)

(-)
(-)

Figure 3. Breast Cancer Receptor Phenotypes
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APPENDIX D: Institutional Review Board (IRB) Forms
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APPENDIX E: Calculation of Power
Dupont WD, Plummer WD: 'Power and Sample Size Calculations: A Review and
Computer Program', Controlled Clinical Trials 1990; 11:116-28. PS, Version 3.1.2.
Input variables on the Dichotomous dialogue box:
• α (alpha): The Type I error probability for a two-sided test. This is the probability that
we will falsely reject the null hypothesis.
• n: For case-control studies, n is the number of case patients. For prospective studies, n
is the number of patients receiving the experimental treatment.
• Power: The probability of correctly rejecting the null hypothesis that the relative risk
(odds ratio) equals 1 given n case patients, m control patients per experimental
patient, and a Type I error probability α.
• p0: For case-control studies, p0 is the probability of exposure in controls. In
prospective studies, p0 is the probability of the outcome for a control patient.
• p1: For case-control studies, p1 is the probability of exposure in cases. In prospective
studies, p1 is the probability of the outcome for an experimental subject.
• m: For independent prospective studies, m is the ratio of control to experimental
subjects. For matched prospective studies, m is the number of control subjects
matched to each experimental subject. For independent case-control studies, m is the
ratio of control to case patients. For matched case-control studies, m is the number of
control patients matched to each case.
Description output: We are planning a study with 2,194 (n) experimental subjects and
1,761 (n*m) control subjects. Prior data indicate that the probability of exposure among
controls is 0.044 (p0). If the true probability of exposure among cases is 0.0645 (p1), we
will be able to reject the null hypothesis that the exposure rates for case and controls are
equal with probability (power) .805 (Power for uncorrected chi-squared test). The Type I
error probability associated with this test of this null hypothesis is 0.05 (α). We will use
an uncorrected chi-squared statistic to evaluate this null hypothesis.
Table 9. Power Calculation
Calculation of Power: Design and Inputs
Type of study
Requested output
How is the alternative hypothesis expressed?
Matched or Independent?
Case-Control?
Uncorrected chi-squared or Fisher’s exact test?
α (alpha)
n
p0
p1
m
Power for uncorrected chi-squared test
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PPV1
Dichotomous
Power
Two proportions
Independent
Case-Control
Uncorrected chi-squared test
0.05
2,194
0.044
0.0645
0.80264357
0.805

APPENDIX F: Supplementary Analyses
Table 10. Extended Risk Data in Study Subset
p-value*
FFDM
DBT
Age Categories, n (%)
<40 years
40-49 years
50-59 years
60-69 years
≥70 years
Race, N (%)
Caucasian
African American
Asian
Other/Unknown
Ethnicity, N (%)
Hispanic
Non-Hispanic
Other/Unknown
Breast Density, N (%)
BI-RADS A
BI-RADS B
BI-RADS C
BI-RADS D
Prior Mammogram(s), N (%)
0
1
2
≥3
BMI, Mean (SD)
Age at Menarche, N (%)
7-11 years
12-13 years
≥14 years
Unknown/Missing
Age at First Birth, N (%)
No births
<20 years
20-24 years
25-29 years
≥30 years
Unknown/Missing
First Degree Fam History, N (%)
Yes
No
Unknown/Missing
Jewish Ancestry, N (%)
Yes
No
Unknown/Missing
*p-value will be calculated from chi-squared test, excluding unknown/missing data. All tests will be two
sided. p-values of <0.05 will be considered statistically significant.
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